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LITERATURE REVIEW 
 
 
1 INTRODUCTION 
 
Gene therapy involves the delivery of exogenous DNA into the target cells in order 
to produce therapeutic protein or to correct a genetic defect. Gene delivery has huge 
potential for treating diseases, regardless, if they are inherent or acquired: a mutated 
gene can be replaced and the gene therapy can take a place of conventional protein 
therapy (Ibraheem et al. 2014). Furthermore, the most significant attractiveness of 
gene therapy lies in the possibility to cure patients for their lifetime with a single 
intervention. Gene therapy may be considered for the treatment of diseases with 
following properties: the severity of condition, the lack of current treatment methods, 
an identified gene defect and a target organ with the sufficient access of gene 
delivery (Tarhini et al. 2011; von der Leyen et al. 2011; Lu et al. 2012; Alton et al. 
2013; Senzer et al. 2013; Alvarez et al. 2014). 
 
In the circulation, naked exogenous DNA is destroyed by nucleases with a half-life 
about ten minutes and the cell uptake of naked DNA is usually poor, thus the 
transfection efficiency of naked DNA is often tried to enhance by physical 
transfection methods (Kawabata et al. 1995; Wang et al. 2013). On the other hand, 
carriers of different kind have been developed to overcome the obstacle of low gene 
delivery efficiency. Both viral and non-viral gene delivery methods have been 
studied to transfer a desired gene to the target cells (Felgner et al. 1987; Wu and Wu 
1987; Boussif et al. 1995; Wolfert et al. 1996; Li et al. 1998; Kay et al. 2001). 
Viruses are natural DNA delivery agents that can be harnessed in gene therapy (Kay 
et al. 2001). Retroviruses, lentiviruses, adenoviruses and adeno-associated viruses 
(AAV) have been modified for the purposes of gene delivery. However, viral gene 
delivery has met significant drawbacks like provoking of immunoresponses, causing 
carcinogenicity and having limited DNA packing capacity. Despite the encountered 
obstacles, Glybera, an AAV vector engineered to express lipoprotein lipase for its 
deficiency, was approved as the first gene delivery treatment by European Medicines 
Agency (EMA) in 2012 (EMA 2012). 
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To overcome the problems related to viral gene delivery, non-viral carrier-mediated 
transfection methods have been developed to mimic the transduction process of 
viruses. Carrier-mediated gene therapy is usually based on cationic polymers or 
lipids that protect DNA from degradation and enable its entry into a cell (Felgner et 
al. 1987; Wu and Wu 1987; Boussif et al. 1995; Wolfert et al. 1996). Hence, the 
success of non-viral gene therapy is largely dependent on the development of carriers 
that can selectively and efficiently deliver a gene to the target cells with minimal 
toxicity. The low transfection efficiency and possible cytotoxicity are the factors that 
have restricted the development of carrier-mediated transfection methods to clinical 
use. In addition to carrier development, DNA engineering is an area under 
investigation that is assumed to enable prolonged gene expression in the target cells 
(Darquet et al. 1997; Schakowski et al. 2001; Wong et al. 2011). 
 
The aim of this literature review is to give an overview to the barriers related to non-
viral gene delivery and to the methods to overcome these obstacles. Carrier-mediated 
transfection methods and DNA engineering are in the focus of this review. Finally, 
an insight is given to the current situation of carrier-mediated gene delivery methods 
in clinical trials and interesting formulations used in human studies recent years are 
highlighted. 
 
 
2 NON-VIRAL GENE DELIVERY 
 
In non-viral gene therapy exogenous DNA is delivered into the nucleus of a cell with 
carrier-mediated or physical transfection methods. Additionally, the administration 
of naked DNA can also be classified as a non-viral transfection method. There are 
many demands for a gene delivery system that need to be met to achieve efficient 
transfection: The target cells are reached selectively, the gene delivery system has 
low cytotoxicity and immunogenicity, transgene expression is sufficiently long and 
there is a possibility to regulate the gene expression if it is needed for the treatment 
of the disease (Ibraheem et al. 2014). Moreover, simple production and 
administration of the medicinal product are also desirable properties for a gene 
delivery system. 
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In carrier mediated or chemical gene delivery, lipids, polymers or their combinations 
usually act as carriers of DNA to form nanoparticles (Felgner et al. 1987; Wu and 
Wu 1987; Boussif et al. 1995; Guo et al. 2002). Polymer/DNA complexes and 
lipid/DNA complexes are called polyplexes and lipoplexes, respectively. In physical 
gene delivery, a physical force is used to weaken cell membranes in order to enable 
DNA penetration into the cells. Ultrasound, electroporation and “gene gun”, based 
on the delivery of DNA coated gold particles by high-voltage electric charge,  are 
examples of physical gene delivery methods (Kim et al. 1996; Yang et al. 1999; 
Canatella and Prausnitz 2001). Despite the interesting possibilities related to physical 
approaches, carrier-mediated gene delivery methods are in the focus of this literature 
review. 
 
In gene delivery, many barriers are encountered before DNA can reach the target cell 
and its nucleus (El-Sayed and Harashima 2013). The use of cationic carriers in DNA 
complexation is based on the observation that cationic carrier can condense anionic 
DNA and thus, protect DNA and enable its entry into the cell and the nucleus 
(Felgner et al. 1987; Wu and Wu 1987; Boussif et al. 1995). Positively charged 
carrier/DNA complexes adsorb to the anionic cell membrane via electrostatic 
interactions which can facilitate DNA penetration into the cell and the properties of a 
carrier can have influence on the cell uptake route (Wong et al. 1999). On the other 
hand, positively charged complexes are also found to bind to proteins in the 
circulation and proteoglycans on the cell membrane, which can lead to complex 
degradation and decrease their transfection efficiency in vivo (Yang and Huang 1997; 
Zelphati et al. 1998; Ruponen et al. 2001). Therefore, negatively charged complexes 
are also studied in gene delivery (Guo et al. 2002; Lehtinen et al. 2011). The 
thorough understanding about the barriers that the gene delivery agent encounters in 
the body enables the development of more efficient gene delivery systems. 
 
 
3 BARRIERS TO NON-VIRAL GENE DELIVERY 
 
The first barrier, that a gene delivery system encounters, is the circulation and its 
components that can disintegrate the carrier/DNA complex (Yang and Huang 1997; 
Zelphati et al. 1998; Godbey et al. 1999). Especially albumin is the protein that has 
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been studied to have interactions with cationic carrier/DNA vehicles in the 
circulation (Zelphati et al. 1998; Dash et al. 1999). Also nucleases, the enzymes that 
degrade DNA, can destroy the free DNA in the circulation (Kawabata et al. 1995). 
Additionally, the gene delivery vehicle needs to reach the target cells, which can 
sometimes be challenging depending on the location of the target cells and the 
administration site of the gene therapy. 
 
 
Figure 1. The cell uptake of naked DNA or carrier/DNA complexes and barriers to 
non-viral gene delivery. A. Naked DNA has poor ability to traverse cell membrane. 
B. Transfection can be facilitated with physical methods like electroporation to make 
transient holes in the cell membrane. C. The endocytosis process of lipoplexes. D. 
The endocytosis process of polyplexes. Endocytosis can be receptor mediated. Inside 
the cell, polyplex and lipoplex should escape from the endosome before degradation 
in lysosomes. After the DNA is released from the endosome, it can be degraded by 
nucleases in the cytoplasm. The DNA needs to enter the nucleus to be transcribed 
into RNA. RNA is then transferred to the cytosol and translated into the protein of 
interest (Wang et al. 2013). 
 
The possible mechanisms for gene delivery vehicles to enter a cell and the barriers 
that naked DNA or carrier/DNA complexes encounter during a transfection process 
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are illustrated in Figure 1. The uptake pathways to the cell can be divided into 
endocytic and non-endocytic routes (Xiang et al. 2012). Clathrin-mediated 
endocytosis (CME), calveolae-mediated endocytosis (CvME), phagocytosis and 
macropinocytosis are considered endocytic pathways. Non-endocytic routes can be 
divided into invasive systems that cover physical methods like electroporation, and 
naturally occurring fusion and penetration. The size of carrier/DNA complexes can 
have influence on the cell uptake route and thus, on the fate of the complex in the 
cell (Rejman et al. 2004). Because of the many barriers that the gene delivery vehicle 
encounters before reaching the nucleus, it is difficult to predict which of the barriers 
represent the rate-limiting factor in the transfection process.  
 
3.1 Uptake into the cell 
 
Clathrin-mediated endocytosis (CME) is a receptor-dependent and clathrin-mediated 
uptake pathway into the cell (Xiang et al. 2012). For example, low-density 
lipoprotein (LDL) and transferrin are taken up by CME. CME process contains 
several phases starting from the activation of a transmembrane receptor ending to the 
forming of an endolysosome. The first step in CME is the binding of a ligand to its 
transmembrane receptor, after which intracellular clathrin-proteins polymerize and 
form a clathrin-coated pit on the inner side of the cell membrane (El-Sayed and 
Harashima 2013). This is followed by the polymerization of dynamin-2-enzyme, a 
kind of GTPase, which takes part in the releasing of a clathrin-coated vesicle (CCV) 
off the cell membrane with the diameter of ~150–200 nm. 
 
In the cytosol, the CCV starts to lose its clathrin-coat followed by the fusion with the 
other vesicles to form an early endosome (El-Sayed and Harashima 2013). The pH of 
the early endosome begins to decrease because of the increased concentration of 
protons pumped by the vacuolar adenosine triphosphatase (ATPase) into the 
endosome. After the acidification, the endosome develops into a late endosome that 
fuses with a lysosome to form an endolysosome. The pH during this process is 
decreased from pH 6,1–6,8 of an early endosome to ~4,5 of an endolysosome. 
Considering gene delivery, the DNA-nanoparticle systems must escape from the 
endosome before the acidification process to avoid DNA degradation. So far, some 
non-viral carriers, like polyethylenimine (PEI) polymer and 1,2-dioleoyl-sn-glycero-
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3-phosphoethanolamine (DOPE) lipid, have been found to have DNA escape 
assisting properties from the endosomes and their properties are described later in 
this review  (Boussif et al. 1995; Koltover et al. 1998; Ur Rehman et al. 2013). 
 
Caveoale-mediated endocytosis (CvME) is based on vesicles called caveoales that 
are located on the cell surface (El-Sayed and Harashima 2013). CvME is typical for 
endothelial cells, muscle cells, fibroblasts, and adipocytes. The main components of 
caveoales are cholesterol and caveolin-1 protein but also dynamin participates in the 
fission reaction of the vesicle (Henley et al. 1998; Xiang et al. 2012). After pinching 
off the cell membrame, caveoales fuse together and form a caveosome (El-Sayed and 
Harashima 2013). According to the latest studies, the intracellular pathway of 
caveosomes leads either to endolysosomes, Golgi apparatus, endoplasmic reticulum 
or transcytosis depending on the cell type (Simionescu et al. 2009; Wong et al. 2007; 
Xiang et al. 2012). However, an unambiguous answer to the intracellular fate of 
caveosomes is not yet obtained. In endothelial cells the content of caveosomes can be 
transcytosed, which means that molecules are transported across a cell within 
caveoales (Simionescu et al. 2009). If caveosomes end up in a Golgi apparatus, 
endoplastic reticulum or are transcytosed, it means that the cargo of the caveosome, 
like nanoparticles, avoid the lysosomal degradation. 
 
Many lipoplexes and polyplexes are studied to utilize both CME and CvME pathway 
to enter the cell (Rejman et al. 2004; Rejman et al. 2005; Wong et al. 2007; Billiet et 
al. 2012). According to cell uptake studies, the uptake of several polyplexes has been 
shown to decrease when either CME or CvME routes are inhibited (Rejman et al. 
2005; van der Aa et al. 2007). Interestingly, the transfection efficiency was decreased 
only when CvME was inhibited, which leads to the possibility that polyplexes are 
transported to the nucleus only via CvME and thus, only CvME leads to the efficient 
transfection. Negatively charged lipoplexes are also shown to favor CvME, while 
cationic lipoplexes are often taken up by CME (Billiet et al. 2012). The size of 
nanoparticles has also been observed to have an influence on the cell uptake route. It 
has been observed that the internalization of microspheres with a diameter of 
<200 nm occurs via clathrin-coated pits, while increasing the size over 200 nm leads 
to the change of the uptake route to the caveoale-mediated internalization (Rejman et 
al. 2004). The larger lipoplexes have been observed to have better transfection 
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efficiency in vitro compared with smaller ones, which is proposed to result from the 
differences in the cell uptake routes (Masotti et al. 2009). 
 
Phagocytosis is a special type of endocytic pathway which is peculiar to professional 
phagocytes such as macrophages but also to the certain other cells like endothelial 
and epithelial cells, including retinal pigment epithelial cells (El-Sayed and 
Harashima 2013). The phagocytic pathway is mediated by cup-like membrane 
extensions to internalize large particles (>1 μm) and the shape of particles is 
observed to have influence on phagocytosis. Following internalization, the 
phagosome fuses to early endosomes and late endosomes resulting in its 
acidification. Especially dendritic cells and retinal pigment epithelial cells have been 
studied as the target cells of gene delivery in cancer and age-related macular 
degeneration (AMD), respectively, and phagocytosis has been suggested as a 
possible uptake route of nanoparticles in these cells (Mannermaa et al. 2005; Strauss 
2005; Steele et al. 2011). 
 
Macropinocytosis called also fluid-phase endocytosis is based on the nonspecific 
uptake of fluid-phase into the cell (Xiang et al. 2012). The destination of the 
macropinosomes is usually an endosome but it varies between different cell types. 
The studying of macropinocytosis in the cell uptake of nanoparticles is challenging 
because of the lack of characteristic membrane proteins or lipid coats that label 
macropinosomes (El-Sayed and Harashima 2013). 
 
3.2 DNA release within cells 
 
Endosomal escape is a significant obstacle concerning the efficiency of non-viral 
transfection (Varkouhi et al. 2011). While many viruses have developed efficient 
methods for endosomal release, non-viral transfection often suffers from deficiency 
to avoid lysosomal degradation (Kay et al. 2001; Varkouhi et al. 2011). Several 
mechanisms have been studied to enable the endosomal release of non-viral vectors 
like pH-buffering effect and fusion with the endosomal membrane (Boussif et al. 
1995; Mönkkönen and Urtti 1998). 
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The proton sponge effect is typical for carriers with high buffering capacity and 
flexibility to swell when protonated (Varkouhi et al. 2011). Cationic polymers with 
nitrogen atoms, like PEI, are proposed to accept endosomal protons (Bousiff et al. 
1995). The protonation is supposed to result in the inflow of chloride anions in the 
endosome, leading to the osmotic swelling of the endosome (Varkouhi et al. 2011). If 
the endosome breaks up, the complexes can be released to the cytosol. 
 
Another example of the endosomal escape process is the flip-flop mechanism of 
lipoplexes, which means that contacting lipid bilayers undergo a phase change and 
the liposome fuse with the endosomal membrane (Zelphati and Szoka 1996; 
Mönkkönen and Urtti 1998).  The change of long range lipid organization between 
Lα (lamellar organization with fluid hydrocarbon chains) and HII (two-dimensional 
hexagonal state) states is required for lipid fusion (Figure 2) (Mönkkönen and Urtti 
1998). Transition between these states takes place at hexagonal phase transition 
temperature (TH). Additionally, the lipids that are able to adopt HII state can also 
facilitate lipid fusion between two bilayers in Lα state. DOPE is an example of a 
lipid that has fusogenic properties (Koltover et al. 1998). 
 
 
Figure 2. The schematic diagram of supramolecular structures of lipoplexes. (A) The 
lamellar Lα phase with alternating lipid bilayers and DNA monolayers. (B) The 
inverted hexagonal HII phase, with cylinders consisting of DNA coated with a lipid 
monolayer arranged in a hexagonal lattice. (Tros de Ilarduya et al. 2010). 
 
In addition to polymers and lipids, many kinds of cell penetrating peptides are 
studied to facilitate endosomal escape by forming pores in the endosomal membrane 
(Varkouhi et al. 2011). An interesting example is a peptide KALA (lysine-alanine-
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leucine-alanine) that can efficiently cause the membrane leakage over the pH range 
4,5–8, which enables the endosomal escape of DNA (Wyman et al. 1997). This 
phenomenon is caused by the conformational change of KALA when the pH is 
lowered. 
 
3.3 Nuclear uptake of DNA and post transcriptional events 
 
Once exogenous DNA is released into the cytoplasm, it needs to reach the nucleus to 
access the transcription machinery (Hsu and Uludağ 2012). The nuclear membrane 
regulates the transport of substances between cytosol and nucleus. The nuclear 
membrane contains aqueous channels called nuclear pore complexes (NPC). In the 
relaxed state, the pore size is ~10 nm allowing only the diffusion of small 
compounds like ions and metabolites through it and the transport of RNA and DNA 
is regulated by an energy-dependent process. Some carriers, like PEI, have been 
observed to promote DNA transport to the nucleus but the mechanism is not known 
(Bieber et al. 2002; Honoré et al. 2005). 
 
The import into the nucleus can also be achieved during mitotic events (Hsu and 
Uludağ 2012). Transfection of polyplexes has shown to be cell-cycle-dependent: the 
nuclear entry takes place in synthesis (S) or miotic (M) phase of mitosis depending 
on the cell line used (Männistö et al. 2005; Grosse et al. 2006). S-phase of the cell 
cycle is characterized by the replication of the genome while at M-phase breakdown 
of a nuclear membrane temporarily removes the physical barrier of the nucleus (Hsu 
and Uludağ 2012). It is likely that both M- and S-phases are correlated to better 
nuclear uptake and more frequent transgene expression, which lead to higher 
transfection efficiency. 
 
The intranuclear trafficking of DNA is the poorly understood aspect of nonviral gene 
delivery. Moreover, when DNA reaches the nucleus, it needs to be transcribed to 
RNA which is observed to be dependent at least on the location of DNA in the 
nucleus (Hsu and Uludağ 2012). Controversial observations have been presented on 
the issue whether DNA must dissociate from its carrier prior to being transcribed 
(Honoré et al. 2005; Hsu and Uludağ 2012). 
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4 CARRIERS FOR NON-VIRAL GENE DELIVERY 
 
Polyplexes, lipoplexes and lipopolyplexes are widely investigated non-viral gene 
delivery systems (Felgner et al. 1987; Wu and Wu 1987; Boussif et al. 1995; Pelisek 
et al. 2006). Size and zetapotential measurement, the gel electrophoresis of 
complexes and DNA relaxation assay are examples of studies that can be conducted 
to predict the stability and the transfection efficiency of complexes (Bertschinger et 
al. 2006; Lehtinen et al. 2008). 
 
4.1 Polyplexes 
 
A polyplex is a complex of a cationic polymer and anionic DNA that is formed via 
electrostatic interactions (Tang and Szoka 1997). Polymers have shown to have 
several desirable properties like enhanced DNA uptake via endocytosis, protection of 
DNA from degradation by nucleases and improved DNA escape from endosomes 
(Boussif et al. 1995; Leong et al. 1998; Ur Rehman et al. 2013). However, the 
possible cytotoxicity of polymers needs to be taken into account when planning their 
use in transfections (Boussif et al. 1995; van de Wetering et al. 1998; Alhoranta et al. 
2011). 
 
The use of cationic polymers in transfections was introduced in 1987 when poly-L-
lysine (PLL) with targeting moiety was shown to have transfection efficiency in vitro 
(Wu and Wu 1987). After that transfection efficiency of several natural and synthetic 
polymers have been studied including polyethylenimine (PEI) (Boussif et al. 1995), 
cationic dendrimers (Kukowska-Latallo et al. 1996), 2-dimethyl(aminoethyl) 
methacrylate (PDMAEMA) (van de Wetering et al. 1998) and carbohydrate-based 
polymers such as chitosan (Leong et al. 1998). PLL/DNA and PEI/DNA complexes 
can be considered as the most studied polyplexes for transfections (Tros de Ilarduya 
et al. 2010). 
 
The production of polyplexes is usually simple, however, the sequence of the 
addition of polymers and DNA during the complexation procedure can influence on 
the particle size (Tros de Ilarduya et al. 2010). Cationic polymers like PEI and 
PDMAEMA-based polymers can condense DNA in particularly small size (150–200 
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nm) while some dendrimers and polylysine complexes form larger particles (>2000 
nm) (Tang and Szoka 1997). The complex size can be decreased by increasing the 
nitrogen/phosphorus (n/p) ratio of complexes, increasing molecular weight or 
branching of the polymer or decreasing salt concentration of the medium (Tang and 
Szoka 1997; van de Wetering et al. 1998; Honoré et al. 2005).  For efficient 
condensation of DNA high enough n/p ratio needs to be used to form stable 
complexes but similarly the cytotoxicity of the complexes with high n/p ratios needs 
to be considered (van de Wetering et al. 1998; Bertschinger et al. 2006; Alhoranta et 
al. 2011). 
 
Poly-L-lysine (PLL) has been studied as a transfection carrier for decades because of 
its excellent DNA condensing properties (Wu and Wu 1987; Kodama et al. 2014). 
PLL is linear polypeptide composed of amino acid lysine which makes it 
biodegradable (Tros de Ilarduya et al. 2010). PLL is observed to bind to plasma 
proteins, especially to albumin, which leads to its fast clearance from the blood 
circulation in vivo (Dash et al. 1999). Additionally, its transfection activity alone is 
poor and therefore PLL is usually modified to improve its efficiency in transfections: 
PLL has been coated with polyethyleinglycol (PEG), targeting ligands have been 
added on it, it has been combined with fusogenic agents or histidine groups have 
been introduced to PLL to have proton sponge effect (Wu and Wu 1987; Wolfert et 
al. 1996; Lee et al. 2002; Hwang et al. 2014). 
 
An example of the recent approaches in gene delivery with PLL is dendrigraft PLL 
(DGL) polymers which are, as opposite to many other dendrimers, biodegradable 
(Cottet et al. 2007; Kodama et al. 2014). Despite promising results in vitro and in 
vivo transfection studies, DGL polymers have been found to induce toxicities, which 
has led to an experiment to coat them with anionic polymer c-polyglutamicacid (c-
PGA) to neutralize the excess of positive charges (Kodama et al. 2014). DGL coated 
with PGA has found to have better transfection efficiency compared with PLL or 
DGL alone in vitro. However, more investigation is needed to figure out if they have 
potential for clinical applications. 
 
Many kinds of modifications of PEG-PLL polymers have been done starting from 
Wolfert and co-worker’s successful studies (Wolfert et al. 1996). One example is the 
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production of the block copolymers of polyethylene glycol and poly-L-lysine linked 
by a pH-responsive poly-L-histidine group (PEG-CH12K18) (Boylan et al. 2012). This 
PEG-CH12K18 has proved to have potential as a carrier probably because of the cover 
of PEG in the circulation and the ability of poly-L-histidine to accept endosomal 
protons and thus, enable endosomal escape. 
 
Polyethylenimine (PEI) is a cationic polymer which can be found as linear and 
branched macromolecule and the backbone of PEI is composed of two carbons 
followed by one nitrogen atom which can be protonated (Figure 3). This leads to the 
effective buffering capacity of PEI at physiological pH (Boussif et al. 1995). 
However, pKa value of PEI is not determined because of several, even over 1000, 
amine groups of PEI depending on its molecular weight. 
 
Figure 3. The chemical structures of linear and branched PEI (Yin et al. 2014). 
 
PEI can form stable complexes with anionic DNA although branched PEI 25 kDa 
condenses DNA more efficiently compared with linear PEI 22 kDa (Dunlap et al. 
1997; Bertschinger et al. 2006). Serum has been observed to bind and inactivate 
polyplexes, however, the use of a more concentrated PEI/DNA solution, a different 
PEI/DNA ratio or a modified surface of the complexes may counteract the negative 
effects of serum on transfection efficiency (Godbey et al. 1999; Moret et al. 2001). 
Free PEI is harmful to the cells probably because of its ability to permeabilize 
membranes but its toxicity is decreased when it is complexed with DNA (Boussif et 
al. 1995). 
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PEI/DNA complexes can enter the cell via a CME and a CvME route (Rejman et al. 
2005). In the earlier studies, the proton sponge property of PEI has been assumed to 
protect DNA from degradation in lysosomes (Boussif et al. 1995). It was 
hypothesized that PEI accepts protons, which has impact on the pH of 
endolysosomes. This was proposed to lead to the inactivation of degradative 
enzymes, after which endolysosomal bursting occurs and PEI/DNA complexes are 
released. However, the hypothesis of endolysosomal bursting is questioned in the 
recent studies. Ur Rehman et al. (2013) have studied the delivery of polyplexes into 
the cell by spinning disk confocal microscopy. They observed that PEI/DNA 
polyplexes did not cause endosomal lysis but a local destabilization of the endosomal 
membrane. That was possibly induced by osmotic or mechanical effect at the site of 
polyplex-endosomal membrane interaction. On the other hand, Rejman et al. (2005) 
concluded that PEI/DNA complexes can reach the nucleus only via CvME route 
which does not necessarily lead to the lysosomes. The cell entry mechanism can vary 
between the particles with varying size and in different cell types, which can lead to 
different results in cell uptake studies. Despite the cell uptake route, DNA has been 
observed to enter the nucleus in the PEI/plasmid complex, which means that DNA 
does not necessarily need to separate from the PEI before nucleus entrance (Honoré 
et al. 2005). 
 
Methacrylamide-based polymer poly 2-(dimethylamino)ethyl methacrylate 
(PDMAEMA) is a pH sensitive compound used as a carrier in transfection studies.  
PDMAEMA is a water-soluble vinyl polymer with tertiary amine side groups formed 
by radical polymerization (Figure 4A) (van de Wetering et al. 1998). The pKa value 
of the side groups is about 8, which leads to their protonation at physiological pH. 
Cationic PDMAEMA condenses DNA and the transfection efficiency of the 
complexes is observed to be dependent on the PDMAEMA/DNA ratio, the molecular 
weight of PDMAEMA and the PDMAEMA-copolymer modifications. The high 
molecular weight of the polymer (>60 kDa) has shown to improve the transfection 
efficiency. The significant benefit compared with many other polymers and 
liposomes for transfection is that PDMAEMA-based polyplexes are resistant to the 
disintegrative impact of serum (van de Wetering et al. 1998). 
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Free PDMAEMA has negative impact on the cell viability, which is observed to 
decrease the transfection efficiency when the high n/p ratios of PDMAEMA/DNA 
complexes are used (van de Wetering et al. 1998). Because of the high toxicity of 
PDMAEMA, the formation of PDMAEMA-based block copolymers has been an 
interesting area of investigation to produce safer PDMAEMA-based carriers 
(Funhoff et al. 2005; Alhoranta et al. 2011). A block copolymer is a polymer made of 
different repeating chemical monomers attached to each other by various types of 
covalent bonds (Hamidi et al. 2012). Block copolymers have ability to self-assemble 
and form micelles in selective solvents, which can be utilized in production of 
carrier/DNA complexes. Copolymers can be divided into star-like, linear, grafted and 
cross-linked copolymers, which have different properties like critical micelle 
concentration (CMC) and hydrodynamic dimensions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. A. The chemical structure of PDMAEMA (Yin et al. 2014). B. The 
structure of linear and star-like PBuA-PDMAEMA and PS-PDMAEMA copolymers. 
Linear copolymers are formed from three blocks and star-like copolymers have six 
arms (Alhoranta et al. 2011). 
 
Funhoff et al. (2005) have produced triblock copolymers with a PDMAEMA-block, 
a hydrophopic poly(butylmethacrylate) (pBMA) part and a PEG block. The purpose 
of PEG is to protect the cells from the cytotoxic properties of PDMAEMA. The 
complexes showed lower cytotoxicity but they could not reach the transfection 
efficiency of non-pegylated PDMAEMA. The pegylation of the polymer or neutral 
zetapotential of complexes might be the reasons for the lower cell uptake. Alhoranta 
A. B. 
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et al. (2011) have produced linear and star-like structured PDMAEMA block 
copolymers. Calix[6]arene was used as a core molecule to form star block 
copolymers with six arms. A hydrophobic core was formed from either polystyrene 
(PS) or poly(n-butylacrylate) (PBuA) and outer block consisted of cationic 
PDMAEMA (Figure 4B). Linear block copolymers are formed from three blocks 
having polystyrene or poly(n-butylacrylate) in the middle and PDMAEMA blocks on 
the edges. In transfection studies, the change in architecture of copolymer was 
observed to have an influence on the transfection efficiency and linear PBuA-
PDMAEMA -based polyplexes were the most effective and promoted high cell 
viability.   
 
4.2 Lipoplexes 
 
Lipoplexes are produced by the interaction of cationic liposomes with DNA. 
Cationic liposomes have many desirable properties concerning transfection like 
biodegrability, low toxicity and non-immunogenicity (Chesnoy and Huang 2000). 
However, the positive results are often obtained only in vitro experiments because of 
the sensitivity of lipoplexes to serum components (Yang and Huang 1997; Zelphati 
et al. 1998). The synthesis of cationic lipid DOTMA and the promising results of the 
transfection studies in vitro in 1987 cleared the way for the production of many 
cationic lipids for gene delivery (Felgner et al. 1987). Lipoplexes are widely studied 
in vitro and many applications are taken as far as to clinical trials (Felgner et al. 
1987; Ruponen et al. 1999; Masotti et al. 2009; Tarhini et al. 2011; von der Leyen et 
al. 2011; Lu et al. 2012; Senzer et al. 2013). 
 
Liposomes are formed spontaneously from phospholipids when the lipids self-
assemble to vesicles in the presence of aqueous medium (Chesnoy and Huang 2000). 
Conventional methods for the production of liposomes are thin film hydration, 
detergent depletion, ether/ethanol injection, reverse phase evaporation and emulsion 
methods. Liposomes are usually produced from cationic lipids that can be combined 
with neutral helper lipid (Ruponen et al. 1999; Masotti et al. 2009 Pozzi et al. 2014). 
Cationic lipids are composed of a hydrophobic anchor, a linker and a head group 
(Figure 5). Oleyl chain (C18:1) is the most common unsaturated alcyl chain and it is 
part of well-known lipids like DOTAP and DOTMA. Cholesterol derivatives are 
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often used in the mixture of double-chain lipids to stabilize liposomes (Masotti et al. 
2009; Pozzi et al. 2014). 
 
The linker of a lipid is located between a hydrophobic anchor and a head group 
(Chesnoy and Huang 2000). Three carbon glycerol skeleton is used as a linker in 
double-chain hydrocarbons. Biodegradable ester, amide or carbamaoyl bonds or non-
biodegradable ether bonds can be used in linkers. The head group of cationic lipids 
have one or more positive charges. Monovalent lipids have a tertiary or a quaternary 
ammonium group that can be chemically modified. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The chemical structure of cationic lipids DOTMA and DOTAP and neutral 
lipids cholesterol and DOPE (Yin et al. 2014). 
 
First synthetized cationic lipid DOTMA is still used in transfection studies and it is a 
part of commercial product Lipofectin which is composed of DOTMA and neutral 
lipid DOPE (Masotti et al. 2009). Other examples of cationic lipids are DOTAP and 
DDAB (Chesnoy and Huang 2000). DC-cholesterol is cholesterol-based cationic 
lipid which is often studied in transfections combined with other cationic lipids. 
Cationic DOSPA is combined with DOPE in commercial product Lipofectamine. In 
cationic lipoplexes, DNA can be packed into the core of the liposome or between the 
lipid layers in multilamellar structure where it is in safe from the degradation (Figure 
2). The incubation time and lipid concentration have been observed to have impact 
into lipoplex structure. 
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The widely used helper lipid in lipolexes is DOPE that is a neutral molecule having 
property to form a hexagonal phase of the lipid layer (Chesnoy and Huang 2000). 
Formation of the hexagonal phase in lipoplexes following interaction with the 
anionic lipids of endsosomes is crucial for DNA release to the cytoplasm. DOPE has 
been shown to control the spontaneous curvature of the lipid monolayer, which leads 
to its fusogenic property (Koltover et al. 1998). Koltover et al. (1998) have observed 
that in DOTAP/DOPE lipoplexes, the natural curvature of the lipid monolayer is 
driven negative because of differences in lipid shapes: cationic lipid DOTAP is 
cylindrically shaped whereas DOPE is conelike. This induces the transition from 
lamellar to hexagonal geometry. It is assumed that the negative curvature of lipoplex 
inside the anionic endosome leads to the expelling of DNA outside of the endosome, 
which saves DNA from lysosomal degradation. When compared DOPE with DOPC 
lipid, that cannot form the hexagonal phase, DOPE improved the transfection 
efficiency of lipoplexes (Zhou and Huang 1994).  Therefore, it can be concluded that 
it is dependent on the geometry of the lipids used in the liposome if the hexagonal 
phase is achieved. 
 
The influence of a DNA condensing agent protamine sulfate (PS) combined with 
liposomes has been studied on the transfection efficiency (Sorgi et al. 1997; Li et al. 
1998; Mannermaa et al. 2005). PS is sulphated, arginine-rich peptide (Mw≈4000–
4250) that is usually purified from the mature testes of fish (Sorgi et al. 1997). In 
sperm, protamine binds DNA to form compact structure and helps to deliver DNA to 
the nucleus of the egg. Thus, it has been considered as an interesting compound in 
gene delivery. In addition to its many desirable properties, it has been used for 
decades as a heparin antagonist and an excipient in insulin formulations, where it has 
shown its low toxicity and immunogenicity. 
 
The influence of PS on the transfection efficiency is studied with liposomes formed 
from DC-cholesterol, Lipofectin, Lipofectamine, DOTAP or DOTAP/DOPE (Sorgi 
et al. 1997; Li et al. 1998; Mannermaa et al. 2005). PS has shown to improve 
transfection efficiency compared with DNA-condensing agent PLL complexed with 
DS-cholesterol liposomes (Sorgi et al. 1997). Additionally, liposomes complexed 
with PS/DNA have showed to have higher transfection efficiency compared with 
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liposomes alone when DS-cholesterol, Lipofectin, and DOTAP/DOPE liposomes 
have been studied. 
 
4.3 Lipopolyplexes 
 
In recent years, studies have been published about the combinations of cationic 
polymers and liposomes to form complexes called lipopolyplexes (Pelisek et al. 
2006; Anwer et al. 2010; Ewe et al. 2014). Lipopolyplexes are forumulated to have a 
polymer/DNA core with a lipid shield that can be PEG-modified to give more 
protection to the complex (Pelisek et al. 2006; Lehtinen et al. 2008; Ewe et al. 2014). 
The lipid shield can be either cationic, anionic or neutral depending on the used 
lipids. It is notable that despite the combination of both polymers and lipids, the 
particle size of lipopolyplexes usually stays between 100–250 nm depending on the 
composition of the lipid shield. In addition, lipopolyplexes have been shown to avoid 
the aggregation of complexes during the storage which is often observed as a 
problem especially with polyplexes. 
 
The cationic lipopolyplexes have shown to improve transfection efficiency compared 
with corresponding lipoplexes and polyplexes (Pelisek et al. 2006). The lipopolyplex 
formulation with a PEI/DNA core shielded with cationic multivalent DOCSPER or 
DOSPER lipid has been shown to have even 400-fold higher transfection efficiency 
compared with the corresponding lipoplexes or polyplexes. The reasons for 
promising results are assumed to lie in efficient endosomal escape when lipids and 
polymers are combined. However, the mixing order of the components of 
lipopolyplexes has been shown to affect significantly the transfection efficiency and 
the DNA condensation with a polymer needs to precede the lipid coating to achieve 
high transfection efficiency (Pelisek et al. 2006). 
 
Anionic glycosaminoglycans (GAGs) are supposed to have interactions with 
positively charged polyplexes and lipoplexes, which has impact on the cellular entry 
and stability of DNA complexes (Ruponen et al. 2001). GAGs are long, negatively 
charged polysaccharides with sulphate groups (Tomar 2008). Because of their 
negative charge, they can trap positively charged ions and water molecules to form a 
gel around the cell that is a support of the extracellular matrix. 
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Anionic lipid-coated DNA complexes are studied to avoid the undesirable 
interactions with carrier/DNA complexes and GAGs (Guo et al. 2002; Lehtinen et al. 
2008). They are developed to cover a positively charged polymer/DNA core from the 
interactions with GAGs by coating the polyplex with an anionic lipid shield. CHEMS 
lipid is negatively charged in high pH value accepting protons when pH decreases. 
Thus, the DOPE/CHEMS lipid shield is supposed to become fusogenic in the acidic 
environment of endosomes. Despite the interesting theory, contradictory results have 
been obtained from the transfection studies (Guo et al. 2002; Lehtinen et al. 2008). 
Guo et al. (2002) obtained positive results when they compared the transfection 
efficiency of lipopolyplexes with corresponding polyplexes without shielding. On the 
other hand, the transfection efficiency of anionic complexes was not as high as non-
coated PEI-DNA complexes according to the studies of Lehtinen et al. (2008). The 
difference in cell lines used in transfections might had impact on varying results. 
 
 
5 DNA ENGINEERING 
 
Gene delivery has been suggested as an optimal therapy for diseases that need 
continuous medication. That leads to the requirement for long term gene expression 
in target cells. However, the integration of a transgene to the chromosomes of a 
target cell is not usually reached with non-viral transfection methods. On the other 
hand, if the integration is random, it can be a mutagenic event and thus undesirable 
(Kay et al. 2001). The silencing of non-integrated genes is often observed as a 
problem with exogenous DNA (Liu et al. 2009). The engineering of DNA is 
proposed to enable prolonged protein expression after transfection. In Table 1 a 
summary of DNA forms and modifications used in non-viral transfections is 
provided. 
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Table 1. DNA forms and modifications used in non-viral transfections. 
 Benefits Drawbacks 
Plasmid 
1) 
- simple and well-known production 
- alternative promoters 
- possible to modify to have episomal 
replication (EBNA-1) 
- bacterial sequences 
S/MARs 
2) 
- destabilize DNA duplex structure 
    expression is increased 
- replication in host cells 
- opposite results in 
transfection efficiency 
studies 
Minicircle 
3) 
- small size (~2–4 kbp) 
 higher diffusion coefficient 
 effective endocytosis 
 better and longer transfection 
efficiency 
- no immunostimulatory sequences 
- time-consuming, labor 
intensive production 
Linear DNA 
4) 
- small size (~1–1,2 kbp) 
- narrow conformation 
- no immunostimulatory sequences 
- production possible synthetically by 
PCR 
 endotoxin free 
- random integration to the 
genome possible 
Abbreviations: Epstein-Barr virus nuclear antigen-1 (EBNA-1); polymerase chain reaction (PCR); 
kilobasepairs (kbp) 
1) Wendelburg and Vos 1998; Clark 2005; Qin et al. 2010 
2) Bode et al. 2006; Wong et al. 2011; Klausner et al. 2012 
3) Darquet et al. 1997; Kay et al. 2010 
4) Schakowski et al. 2001; Hirata et al. 2007 
 
5.1 Plasmids 
 
Plasmids are circular, double-stranded molecules of DNA which can replicate 
autonomously in their host cells (Clark 2005). They have been found both 
prokaryotic and eukaryotic cells but most plasmids inhabit in bacteria. Plasmids are 
negatively charged because of the anionic phosphate groups of DNA. They can have 
the topology of supercoiled, open-circular or linear, but in transfection studies 
supercoiled plasmid has observed to have the highest transfection efficiency in 
mammalian cells (Cherng et al. 1999). That is probably caused by the lower 
susceptibility of supercoiled DNA to nucleases. In addition to topology, the size of 
plasmid has observed to have an influence on the transfection efficiency: smaller 
plasmid molecules have shown to have higher efficacy in transfection compared with 
larger ones (Kreiss et al. 1999). Nuclear entry via the nuclear pores might be 
dependent on plasmid size, which has an influence on the transfection efficiency 
especially in non-dividing cells. 
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Usually viral cytomegalovirus (CMV) promoter is used in non-viral transfection 
since it has been shown to have high expression level of transgenes compared with 
many other viral promoters (Li et al. 1992; Qin et al. 2010). Because of the viral 
background of CMV promoter, the duration of the protein expression regulated by 
human origin promoters is considered longer in transfections to human stem cells 
because of the silencing of genes with CMV promoter (Liu et al. 2009). The other 
examples of promoters used in mammalian cells are the simian virus 40 early 
promoter (SV40), human ubiquitin C promoter (UBC), human elongation factor 1a 
promoter (EF1a), mouse phosphoglycerate kinase 1 promoter (PGK) and chicken b-
Actin promoter coupled with CMV early enhancer (CAGG) (Li et al. 1992; Qin et al. 
2010).  
 
One approach to modify plasmid to improve the transgene expression duration is to 
modulate the origin of plasmid replication (ori) region. Epstein–Barrin virus (EBV) -
based vectors carry two essential elements for the replication of the EBV genome: 
oriP and Epstein-Barr virus nuclear antigen-1 (EBNA-1) gene coding a replication 
initiation factor (Lindner and Sugden 2007). EBV has ability to maintain its genome 
as an extrachromosomal replicon in the cell and to steal the cellular DNA replication 
machinery for its replication using oriP and EBNA-1. oriP is a region of (EBV) 
chromosome that supports the episomal replication and stable maintenance of 
plasmids in human cells when EBNA-1 protein is bound to it.  This property can be 
used for plasmid engineering combining the oriP region and the gene coding 
EBNA-1 in plasmid used in transfection (Wendelburg and Vos 1998).  Plasmids 
expressing EBNA-1 can episomally replicate in the host cells during a cell division, 
which enable the cell to maintain the plasmid number. 
 
Scaffold matrix attachment regions (S/MARs) are AT-rich sequences that are the 
sites of attachment between the nuclear matrix and DNA in eukaryotic cells (Bode et 
al. 2006). The nuclear matrix is formed by a network of proteins that consists of 
nuclear pores, a nuclear lamina, a residual nucleolus and an internal fibrillar–globular 
network. Attaching to the nuclear matrix, S/MARs are suggested having a role in 
chromatin organization, replication and gene expression (Käs et al. 1993). They can 
prolong gene expression by destabilizing DNA duplex structure which is caused by 
base-unpairing regions (Bode et al. 2006). Furthermore, S/MARs are also observed 
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to drive plasmid DNA replication. Incorporation of S/MARs into a plasmid has 
enabled plasmid to replicate and establish mitotic stability in hepatocytes at a 
detectable level for three months in adult mice (Wong et al. 2011). Contrary, 
Klausner et al. (2012) have studied S/MAR plasmid for corneal transfection in rats. 
They compared the transfection efficiency of nanoparticles with different plasmid 
types and noticed that transfections with S/MAR plasmid did not achieve higher 
transfection efficiency compared with plasmids without S/MAR sequences. 
 
5.2 Minicircles 
 
The modifications to polyadenylation, a transcriptional termination sequence and the 
backbone elements of plasmids have been shown to increase the non-viral 
transfection efficiency in vivo (Hartikka et al. 1996). In addition, the small size of 
DNA molecule has been observed to have benefits in transfection (Kreiss et al. 
1999). These factors have led to plasmid engineering to produce recombinant 
supercoiled DNA molecules, called minicircles. The minicircles lack of bacterial 
origin backbone sequences, like antibiotic resistance gene and immunogenic 
unmethylated CpG motifs, containing only the therapeutic expression cassette 
(Darquet et al. 1997). 
 
The production of minicircles is based on a parental plasmid which contains a cloned 
transgene expressing cassette in the bacterial backbone (Figure 6) (Kay et al. 2010).  
This parental plasmid has two attachment (attB and attP) sites of ФC31 integrase that 
are in the same orientation in the same replicon. According to the protocol of Kay et 
al. (2010), parenteral plasmids are introduced to a genetically modified E. coli strain 
where the replication takes place. The replication is performed by ФC31 integrase 
that converts a parenteral plasmid at the temperature of 37 °C to a minicircle with a 
transgene and a miniplasmid with bacterial backbone. After the replication, an I-SceI 
endonuclease degrades undesirable miniplasmid when the endonuclease targets the 
special degradation sites presented only in the miniplasmid and parenteral plasmid. 
Both ФC31 integrase and I-SceI endonuclease are under the control of the presence 
of arabinose, thus the reactions can be regulated. 
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Figure 6. The figure shows the production model of minicircles. Two attachment 
(attB and attP) sites of ФC31 integrase are in the same orientation in the same 
replicon. The replication is performed by ФC31 integrase when L-arabinose is 
present. Parenteral plasmid and mini plasmid are degraded by endonuclease after 
minicirlce formation (Gaspar et al. 2014). 
 
Darquet et al. (1997) have studied the transfection efficiency of minicircles 
compared with plasmid in several mammalian cell lines. They found that the 
production of a marker protein was from two- to ten-fold higher compared the 
transfection efficiency of minicircle with plasmid. Chen et al. (2003) have shown 
that even 560-fold production of marker protein can be achieved with the 
transfection of minicircle compared with plasmid in mice. The transgene expression 
was observed for three weeks. 
 
In addition to transfection efficiency issues, minicircles are considered safer 
compared with the plasmid DNA (Darquet et al. 1997). The reason assumed to lie in 
the shortage of CpG bacterial sequences that act as the adjuvants of the immune 
system. The other significant factor is the risk of recombination of an antibiotic 
resistance gene with plasmids in endogenous Enterobacteriacae, which could lead to 
a selective advantage of these bacteria if the antibiotic in question is administered. 
 
5.3 Linear DNA 
 
Linear DNA vectors are developed to improve the safety and the efficiency of 
transfections and they can be divided into polymerase chain reaction (PCR) 
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amplified DNA and minimalistic, immunologically defined gene expression 
(MIDGE) vectors (Schakowski et al. 2001; Hirata et al. 2007). Synthetic, PCR 
amplified DNA and MIDGE vectors contain a promoter, a coding gene and a RNA 
stabilizing sequence (Figure 7). As opposite to PCR products, the units of MIDGE 
are combined with two short oligonucleotide hairpin structures that protect it from 
the degradation by nucleases (Schakowski et al. 2001). MIDGE vectors are produced 
from plasmid DNA digesting the plasmid with EcoRI endonuclease enzyme and 
ligating the formed fragments to hairpin oligoDNAs. OligoDNAs are produced by 
chemical DNA synthesis. Unligated fragments are digested and MIDGE vectors are 
purified by anionic-exchange chromatography. 
 
 
 
Figure 7. MIDGE vector is composed of a promoter, a transgene, a RNA stabilizing 
sequence (SV40 PA) and hairpin-like oligoDNAs (Schakowski et al. 2001). 
 
The transfection efficiency of MIDGE vectors is compared with plasmid in vitro 
studies with encouraging results (Schakowski et al. 2001). Higher transfection 
efficiency of MIDGE lipoplexes was observed in comparison with plasmid 
lipoplexes. The low content of CpG sequences is suggested improving transfection 
efficiency. In addition, MIDGE vectors complexed with liposomes have been studied 
in DNA vaccination in mice (Endmann et al. 2014). Endmann et al. (2014) observed 
high immune responses which were explained by the high expression of transgene 
coding immunostimulatory cytokine. The vector DNA was detected still after two 
months after transfection in several tissues. However, more studies about the possible 
integration of MIDGE to the host cell genome are needed. 
 
 
6 CARRIER MEDIATED GENE DELIVERY IN CLINICAL TRIALS 
 
None of the medicinal product using non-viral transfection methods has yet a 
marketing authorization in European Union although interesting clinical trials have 
been conducted in the past few years (Table 2). Concerning both viral and non-viral 
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transfection methods, it has been estimated that globally over 2000 gene therapy 
clinical trials have been approved from January 1989 till June 2014 (Journal of Gene 
Medicine 2014). The first clinical trial using gene delivery was conducted in 1989 
and it was a gene-marking study of tumor-infiltrating lymphocytes by retroviral 
transdution (Rosenberg et al. 1990). During the recent years, 100±20 gene therapy 
clinical trials have been conducted annually (Journal of Gene Medicine 2014). 
However, AAV vector based Glybera is the only gene therapy medicinal product 
with the marketing authorization in European Union so far (EMA 2012). 
 
Because the data of all the approved clinical trials is not publicly available, it is 
impossible to gather the comprehensive summary of approved or conducted clinical 
trials. However, in Figure 8 collects the information on the approved gene therapy 
clinical trials worldwide classified by the carriers or the indications but the figures 
are only approximates. Viral transduction can be considered the most investigated 
gene delivery method in clinical trials during the time (Figure 8). The studying of 
non-viral transfection methods is still in the beginning and the administration of 
naked DNA is the most used non-viral transfection method (17,7 %), while 
lipofection covers only 5,3 % of gene therapy clinical trials. The common indications 
in gene therapy clinical trials are cancer, infectious and cardiovascular diseases and 
monogenic diseases (Figure 8). 
 
Clinical trials can be divided in four phases (I–IV) although the border between the 
phases is not always clear (EMA 1998). In phase I trials, researchers usually test a 
new drug in a small group of healthy volunteers or patients for to evaluate its safety, 
tolerability, pharmacokinetics and possibly pharmacodynamics. The aim of phase II 
studies is usually to explore the therapeutic efficacy of the study drug in patients and 
to determine the dose for phase III trials. In phase III trials, the drug is given to large 
groups of patients to confirm its effectiveness and safety and provide a basis for 
marketing approval. After the drug has been approved, phase IV studies are done to 
gather information on the drug's effect in various populations after long-term use. 
Phase IV trials are not considered necessary for approval of the drug but they can be 
used for optimizing the drug's use. 
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Figure 8. The approximate division between gene delivery carriers and indications in 
approved clinical trials worldwide between Jan 1989–Jun 2014 (Journal of Gene 
Medicine 2014). 
 
In Table 2 is collected clinical trials in which carrier-mediated gene delivery has 
been studied and the results have been published in the past five years. All the 
clinical trials in Table 2 are phase I or phase II studies which tells about the early 
state of the investigation of these drugs and further studies are needed if a marketing 
authorization is in the target. Liposomes complexed with plasmid DNA have been 
used in the most of the clinical trials with varying indications in Table 2. 
Biodegrability, low toxicity and non-immunogenicity are properties connected to 
cationic lipids, which probably leads to their wider investigation compared to 
polyplexes in clinical trials  (Chesnoy and Huang 2000; Tarhini et al. 2011; von der 
Leyen et al. 2011; Lu et al. 2012; Senzer et al. 2013). 
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Table 2. The carrier-mediated gene delivery in clinical trials. Carrier-mediated gene 
delivery clinical trials are collected in the table when their results have been 
published in 2009–2014. 
Carrier DNA 
form 
Trans-
gene 
Disease Phase Reference 
DOTAP/DOPE liposomes 
labelled with anti-
transferrin receptor 
(SGT-53) 
plasmid p53 Advanced 
solid tumors 
I Senzer 
et al. 2013 
DOTAP/cholesterol 
liposomes 
plasmid TUSC2 Lung cancer I Lu 
et al. 2012 
D-cholesterol/DOPE 
liposomes 
plasmid NOS Restenotic 
coronary 
artery lesion 
I von der 
Leyen 
et al. 2011 
Cholesterol/DOTIM 
liposomes 
plasmid MnSOD Lung cancer I Tarhini 
et al. 2011 
PEG/PEI/ 
cholesterol (PPC) 
lipopolymer (EGEN-001) 
plasmid IL-12 Ovarian 
cancer 
I Anwer 
et al. 2010 
PPC lipopolymer 
(EGEN-001) 
plasmid IL-12 Ovarian 
cancer 
I Anwer 
et al. 2013 
PPC lipopolymer 
(EGEN-001) 
plasmid IL-12 Ovarian, 
fallopian 
tube or 
primary 
peritoneal 
cancer 
II Alvarez 
et al. 2014 
CL22 peptide plasmid Melan A, 
gp100 
Melanoma I / II Steele 
et al. 2011 
Abbreviation: interleukin-12 (IL-12); manganese superoxide dismutase (MnSOD); nitric oxide 
synthase (NOS); tumor suppressor p53 (p53) tumor suppressor gene (TUSC2) 
 
 
As an example of a clinical trial conducted with lipoplexes, the gene therapy to the 
advanced solid tumors has been investigated using DOTAP/DOPE liposomes 
(Senzer et al. 2013). The liposomes were labeled with a single-chain antibody 
fragment of an anti-transferrin receptor to target them to the tumor cells expressing 
transferrin glycoprotein receptors. The p53 transcription factor gene, that induces cell 
cycle arrest, was transfected to the cancer cells. The presence of transgene in the 
tumor was evaluated purifying DNA from the biopsies. Reverse transcription PCR 
with specific primers for the exogenous p53 gene was used to determine transgene 
expression in the samples. According to the PCR assessment, transgene was present 
in the biopsies and thus the lipoplexes reached the target site after intravenous 
infusion. 
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Another example of a lipoplex formulation studied in a clinical trial is 
cholesterol/DOTIM/plasmid lipoplexes that have been studied in combination with 
chemotherapy and thoracic radiotherapy in lung cancer (Tarhini et al. 2011). In the 
trial, the target of the study drug was interesting: The plasmid was encoding 
manganese superoxide dismutase (MnSOD) protein to protect the esophagus from 
the adverse reactions of chemoradiotherapy by decreasing the expression of 
inflammatory cytokines in the esophagus of the patient. Because the target cells were 
located in the esophagus, the study drug was given orally to the patients. Toxicities 
were not observed after the lipoplex administration. On the other hand, neither 
detectable amounts of transgene were found in the esophagus. 
 
In addition to lipoplexes, the results of the clinical trial using peptide as a carrier of 
DNA has been published during the recent years. Steele et al. (2011) have studied a 
dendritic cell therapeutic cancer vaccine in melanoma using CL22-peptide carrier. 
CL22 is a peptide with a lysine rich N-terminus that is supposed to be responsible for 
its good DNA condensation property and a C-terminal influenza nucleoprotein 
sequence that is believed to comprise an epitope presented on the cells of 
immunologic defense (Haines et al. 2001). In the clinical trial, dendritic cells were 
transfected ex vivo and the patients were vaccinated with the transfected dendritic 
cells (Steele et al. 2011). Plasmid complexed with CL22-peptide was encoding 
melanocyte differentiation antigens, melan A and gp100. Thus, the dendritic cells 
expressing the antigens were suggested activating T- and B-lymphocytes against the 
cancer cells in melanoma. During the study the evidence of the immunogenicity of 
the vaccine was obtained, in addition, the vaccine was concluded to be safe and 
tolerated.  
 
Lipopolyplex formulation combining PEG, PEI and cholesterol (PPC) complexed 
with plasmid encoding interleukin-12 (IL-12) has been studied in three clinical trials 
(Table 2). In phase I trials patients with ovarian cancer were enrolled, while in phase 
II trial the inclusion criteria were broadened also to the patients with fallopian tube 
and primary peritoneal cancer. In phase I trials, IL-12 has been shown to increase 
interferon-γ (IFN-γ) concentrations, which is supposed to lead to the inhibition of the 
tumor growth (Anwer et al. 2010 and Anwer et al. 2013). Lipopolyplexes were 
observed to be well-tolerated in the trials. However, in the phase II trial three patient 
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withdrew from the study because of adverse effects like elevated creatinine values, 
neutropathy, abdominal pain and anemia (Alvarez et al. 2014). In addition, the study 
drug showed only limited activity. Thus, the phase II trial with the highest dose level 
questioned the benefit-risk-ratio of the study drug in ovarian cancer. Considering the 
formulation of the study drug, the cytotoxicity of PEI is well known from in vitro 
studies, which leads to the possibility that PEI could have had influence on the low 
tolerability of the study drug (Boussif et al. 1995; Godbey et al. 1999).  
 
 
7 CONCLUSIONS 
 
Gene delivery encounters barriers both outside and inside the cell and they need to be 
overcome to achieve the sufficient transfection efficiency in the target cells. Carrier-
mediated transfection methods and DNA engineering are studied to develop the 
efficient gene delivery methods. Polyplexes and lipoplexes are the most investigated 
non-viral gene delivery vehicles and they have many desirable properties: They can 
protect DNA from nucleases, facilitate the cell entry and enable the endosomal 
escape of DNA. Lipopolyplexes are also investigated to combine the benefits of both 
polymers and lipids to one formulation. DNA engineering aims at achieving long-
term transgene expression in the transfected cells by decreasing the bacterial 
components of plasmid DNA or enabling the endosomal replication in the host cells. 
The careful characterization and optimization of complexes can enable one to form 
the gene delivery system with sufficient stability and successful gene expression. 
Carrier-mediated gene delivery has been investigated in clinical trials, however, 
these formulations have not yet received any marketing authorization in European 
Union. Insufficient efficiency and possible toxicity are the main obstacles of carrier-
mediated gene delivery systems that need to be overcome to achieve the potential 
treatment for the disease in interest. 
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EXPERIMENTAL WORK 
 
 
8 INTRODUCTION 
 
Gene delivery has been suggested as a treatment for many retinal diseases like age 
related macular degeneration (AMD) that is the most common cause of blindness in 
the industrial countries (Fernández-Robredo et al. 2014). It has been estimated that 
AMD will affect even about 196 million people worldwide in 2020 because the 
prevalence of AMD is increased in elderly and the population is ageing (Wong et al. 
2014). In addition to high age, metabolic, functional, genetic and environmental 
factors have been observed to have an influence on the chronic disease progression, 
and two subgroups of AMD, atrophic and exudative, can be distinguished (Strauss 
2005; Fernández-Robredo et al. 2014). 
 
At the moment, no curative treatment is available for AMD and the need for new 
therapies increases all the time (Fernández-Robredo et al. 2014). Moreover, drug 
administration to the posterior segment of the eye is challenging leading to the 
situation where many diseases of the back of eye do not have an efficient treatment 
(Urtti 2006). Despite few intravitreally administered anti-VEGF biologics have been 
developed, curative therapy for AMD or the other retinal diseases is not yet found  
(Fernández-Robredo et al. 2014; Solomon et al. 2014). Prolonged action dosage 
forms and gene delivery are the interest of drug development at the moment because 
of longer drug administration intervals and better efficiency. 
 
In gene therapy, the disease is treated with exogenously given DNA that is 
transcribed and translated to produce the therapeutic protein. Gene modifications can 
be combined with the cell replacement when the cells are transfected with the gene 
of interest before transplantation (Johnen et al. 2012). Retinal pigment epithelium 
(RPE) is a possible but demanding target for gene therapy in retinal diseases 
(Remington 2012; Vellonen et al. 2014). Especially, non-viral transfection is hoped 
to open new opportunities to deliver genes into RPE cells in vivo compared with viral 
vectors which have many concerns including immunogenicity and low DNA payload 
31 
 
capacity (Kay et al. 2001). To make non-viral gene delivery more efficient and safe, 
new gene delivery vehicles need to be found and studied in vitro and in vivo. 
 
8.1 Retinal pigment epithelial cells 
 
The retina is a neural layer that forms the innermost coat of the eye (Figure 1) 
(Remington 2012). It is located between a choroid and a vitreous. The outermost 
layer of the retina consists of RPE and it is embryologically derived from the 
external stratum of the optic cup (Garron 1963). RPE cells form a monolayer which 
is tightly adherent to the choroid. The shape of these cells is dependent on the site in 
the retina where they are located varying from hexagonal structure to longer and 
narrower (Garron 1963; Remington 2012). RPE cells have melanosomes that are 
pigment granules absorbing light. The pigmentation density is the highest in the 
macula and in the equator of the retina. The RPE cells have microvilli on the apical 
site and the cells form tight junctions between each other (Garron 1963). 
 
 
 
 
 
 
Figure 1. A. Anatomy of the eye. The retina is a neural layer that forms the innermost 
coat of the eye and it is located between a choroid and a vitreous (National Eye 
Institute 2014); B. Layers of the retina [outer nuclear layer (ONL); outer plexiform 
layer (OPL); inner nuclear layer (INL); inner plexiform layer (IPL)]. A RPE cell 
layer is the outermost layer of the retina and it is located between photoreceptors and 
choroid (Remington 2012). 
 
RPE cells have many functions that support the health of photoreceptors (Strauss 
2005; Remington 2012). The RPE layer and the endothelial cells of retinal capillaries 
A. B. 
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form the outer and the inner blood-retina-barrier (BRB), respectively. The outer BRB 
controls the transfer of nutrients to the photoreceptors and removal of metabolites, 
ions, and excess of water into the choriocapillaris (Strauss 2005). The RPE is a part 
of visual cycle which is responsible for the reisomerization of all-trans-retinal from 
photoreceptors to 11-cis-retinal and its return to the photoreceptors. RPE cells also 
have phagocytosis activity, which prevents the accumulation of photo-damaged 
proteins and lipids in the photoreceptors. The photoreceptors secrete discs that 
contain light-induced toxic substrates and RPE cells phagocytize and transfer them to 
the lysosomes. Other functions of RPE cells are to absorb scattered light and produce 
a variety of growth factors like vascular endothelial growth factor (VEGF) and 
pigment epithelial derived factor (PEDF) (Steele et al. 1992; Adamis et al. 1993). 
Furthermore, RPE also maintain the immune privilege of the eye by secreting 
immunosuppressive factors (Strauss 2005). 
 
Because of many roles of RPE cell layer, its well-being is essential to the normal 
function of neural retina (Strauss 2005). RPE and photoreceptors can be considered 
as a functional unit and dysfunction in any task of RPE can lead to the progression of 
blinding eye diseases. The decreased absorption of light, oxidative stress, diminished 
phagocytosis and inflammation are examples of processes in the background of 
AMD. Furthermore, the mutations of genes can promote disease progression. For 
example, mutation in ABCA4 transporter gene has impact on the cycle of all-trans-
retinal and it leads to the different forms of retinal degenerations (Weng et al. 1999). 
Another example is an imbalance in production of growth factors like VEGF in RPE, 
which causes the proliferation of the cells (Adamis et al. 1993; Strauss 2005). 
 
8.2 In vitro -cell models for studying transfection to the retina 
 
ARPE-19 is a spontaneously arising, continuous human retinal pigment epithelial 
cell line that is used in transfection studies (Dunn et al. 1996; Mannermaa et al. 2005; 
Subrizi et al. 2009). It has highly epithelial morphology, normal karyology and 
functional properties characteristic of RPE cells, which makes it useful for in vitro 
studies (Dunn et al. 1996). The drawbacks of the cell line are an incorrect phenotype 
if not grown on the filters and a low melanin formation level (Vellonen et al. 2014). 
In addition, ARPE-19 subcultures contain both mortal and immortal cells, and 
33 
 
between them can exist differences (Kozlowski 2014). The estimated doubling time 
for ARPE-19 cells is 24 hours and the passage numbers 25–35 can be used in vitro 
studies (Dunn et al. 1996; Subrizi et al. 2009). 
 
Human embryonic stem cell-derived RPE (hESC-RPE) cells can also be utilized as a 
cell model of RPE (Vaajasaari et al. 2011; Reynolds and Lamba 2014; ScienCell 
Research Larboratories 2014). hESC-RPE can be grown for the purposes of cell 
transplantation or in vitro studies (Vaajasaari et al. 2011; Reynolds and Lamba 
2014). Embryonic stem cells are derived from the inner cell mass of blastocyst and 
the differentiation toward RPE can be induced by removing basic fibroblast growth 
factor and feeder cells from the serum-free conditions. According to the protocol of 
Vaajasaari et al. (2011), typical pigmented morphology, the expression of RPE-
specific markers, secretion of PEDF and tight junctions were achieved after the 
differentiation of hESC-RPE. hESC-RPE are indicated to resemble nearly human 
fetal RPE though some differences in gene expression have been found (Liao et al. 
2010). Another possibility is to use human embryonic primary RPE cells isolated 
from the retina of an embryo as a cell model of RPE thought limited availability is 
related to it. Human primary RPE cells can be cultured for ten doublings in vitro but 
the properties of original tissue can be lost during subculturing (ScienCell Research 
Larboratories 2014; Vellonen et. al 2014). 
 
The human endothelial hybridoma (EaHy 926) cell line is produced fusing human 
umbilical vein endothelial cells with a human carcinoma cell line (Edgell et al. 
1983). The EaHy 926 cells have been observed to be stable at least till 30 passages 
(Emeis and Edgell 1988). In this study, endothelial cells are used as a cell model to 
illustrate the transfection possibilities in choroidal neovascularization. For example, 
exudative AMD is characterized by the proliferation of abnormal vessels in the 
choroid which makes endothelial cells a potential target of gene therapy (Fernández-
Robredo et al. 2014). 
 
8.3 Non-viral transfection strategies for retinal diseases 
 
Non-viral transfection demands efficient carriers and DNA modifications to compete 
to viral transfection methods. The prolonged expression of a transgene is needed to 
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achieve the stable and long-term production of a therapeutic protein in the target 
cells. The modifications of DNA can have a significant impact on the transfection 
efficacy and the duration of transgene expression (Darquet et al. 1997). Because 
minicircles are devoid of bacterial backbone, they are shown to produce higher and 
longer transgene expression compared with plasmids. On the other hand, plasmid 
expressing Epstein–Barr virus nuclear antigen 1 (EBNA-1) is supposed to have long 
transfection efficiency as well because of its episomal replication (Adams 1987). The 
plasmids with inherent ability to replicate and retain in the nucleus are believed to 
provide sustained gene expression. 
 
In earlier studies, micelles based on PDMAEMA structure (Alhoranta et al. 2011), 
DOTAP/DOPE/PS/DNA lipoplexes (Mannermaa et al. 2005) and lipid coated DNA 
complexes (LCDCs) (Lehtinen et al. 2008) are used to study transfection efficiency 
in vitro with encouraging results. PDMAEMA-based copolymers are observed to 
have reasonable transfection efficiency in ARPE-19 cells (Alhoranta et al. 2011). 
DOTAP/DOPE/PS/DNA lipoplexes are also shown to transfect ARPE-19 cells and 
the transgene has been expressed for two months from the transfection (Mannermaa 
et al. 2005). On the other hand, LCDCs have not convinced as a gene delivery 
vehicle in ARPE-19 cells but because of their attractive structure, the composition of 
LCDCs can be modified for new transfection studies (Subrizi 2004). 
 
Transfection studies with above mentioned carriers complexed with EBNA-1 
plasmid or minicircles have not earlier been conducted. Complexing the carriers with 
the engineered DNA forms is hypothesized to enable an increase in their transfection 
efficiency and prolonged transgene expression. Thus, transfection studies to RPE and 
endothelial cells with these complexes is an interesting subject of research that 
targets to the gene delivery to the posterior eye in the future. 
  
 
9 AIMS OF THE STUDY 
 
The aims of this experimental work were to investigate new gene delivery systems 
for the diseases of the posterior eye. Non-viral gene delivery to dividing RPE cells 
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and endothelial cells was studied in vitro using several carrier/DNA combinations. 
The objectives of this study can be divided into the following points: 
1) Characterize and optimize carrier/DNA complexes for transfections. 
2) Evaluate and compare the transfection efficiency and the toxicity of 
PDMAEMA-based complexes, DOTAP/DOPE/PS/DNA lipoplexes and 
LCDCs with the positive control in RPE and endothelial cells. 
3) Evaluate the significance of DNA modifications to the duration and the 
efficiency of marker protein secretion when episomal plasmid or minicircles 
are used. 
4) Determine the most optimized carrier/DNA complexes to transfect RPE and 
endothelial cells. 
 
 
10 MATERIALS AND METHODS 
 
10.1 Materials 
 
1,2-dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP, Mw=698,55 
g/mol, #890890), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE, 
Mw=744,05 g/mol, #850725) and dioleoylglycerol (diolein, Mw=620,99, #D8894) 
were used as 10 mg/ml stock solutions in chloroform. 1,2-dihexadecanoyl-sn-
glycero-3-phosphoethanolamine (DPPE, Mw= 691,96, #850705) was dissolved in 
chloroform/methanol (9:1 v/v) mixture in concentration of 9 mg/ml. The lipids were 
purchased from Avanti Polar Lipids (Alabaster, AL, USA) except to diolein that was 
obtained from Sigma-Aldrich (St. Louis, MO, USA). Branched polyethylenimine 
(PEI, Mw≈25 000 g/mol, #40872-7) used as 0,9 μg/μl in H2O pH 7,2, 
cholesterolhemisuccinate (CHEMS, Mw=486,73 g/mol, #C6512) 10 mg/ml in 
chloroform, protamine sulfate (PS, Mr≈5000–10 000, #P3369) 1 μg/μl in H2O and 
dextran sulphate sodium salt (DS, Mr=40 000, #42867-56) 10 mM in H2O were also 
purchased from Sigma-Aldrich. Star-like and linear block copolymers, polystyrene 
with cationic 2-(dimethylamino)ethyl  methacrylate (PS36200-PDMAEMA26400 
and PDMAEMA26400-PS36200-PDMAEMA26400; Mw[PS]=36 200 g/mol; 
Mw[PDMAEMA]=26 400 g/mol) and poly(n-butyl-acrylate) with 2-
(dimethylamino)ethyl methacrylate (PBuA4700-PDMAEMA12400 and 
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PDMAEMA33000-PBuA38700-PDMAEMA33000; Mw[PBuA]=4700 g/mol; 
Mw[PDMAEMA in linear copolyer]=12 400 g/mol or Mw[PDMAEMA in star-like 
copolyer]=33 000 g/mol) were synthesized by Anu Alhoranta at the Department of 
Chemistry, laboratory of polymer chemistry in the University of Helsinki. 
 
10.2 Production of plasmid DNA and minicircles 
 
The secreted alkaline phosphatase (SEAP) marker gene coding plasmid with 
cytomegalovirus (CMV) promoter and Epstein-Barr virus (EBV) nuclear antigen 
expression vector (EBNA-CMV-SEAP) was amplified in Escherichia coli (E. coli). 
The plasmid was purified by column separation according to the manufacturer’s 
instructions (QIAfilter Plasmid Giga Kit, #12291, Qiagen, USA) and the plasmid 
was dissolved in TE-buffer (10 mM Tris, 1 mM EDTA, pH 7,4). 
 
The purity of plasmid was enhanced by plasmid DNA precipitation. 0,1 volume 
of  3 M sodium acetate pH 5,2 at +4°C and 2,5 volumes of absolute alcohol (Aa) 
at -20°C was added to plasmid in TE-buffer and the solution was vortexed. After 
incubation at -20 °C for 30 min, the solution was centrifuged at 15 000 g for 30 min 
at +4 °C. Supernatant was discarded, and the DNA pellet was washed with 1 ml 
70 % EtOH at -20 °C inverting the tube a couple of times, after which the 
centrifugation was repeated for 20 min with the same settings as earlier described. 
The supernatant was discarded and the DNA pellet was dried in the lyophilizator. 
After the pellet was dry, DNA was dissolved in TE buffer pH 7,4. The plasmid was 
stored in TE-buffer at the concentration of 1,91 µg/µl at +4 ⁰C and the concentration 
of DNA was measured at the wavelength of 260 nm by SPECTROstar Nano (BMG 
Labtech, Germany). 
 
The plasmid was identified by digestion and electrophoresis. For restriction 
endonuclease reaction, the regents were added to H2O in the following order: 2,0 µl 
of Buffer D, 0,5 µl of bovine serum albumin (BSA) x100, 1 µg of plasmid, and 20 IU 
of Xbal enzyme and H2O to 20 µl. The solution was incubated at 37 °C for 2 h and 
the electrophoresis was conducted in 1 % (w/v) agarose gel with 0,15 µg/µl ethidium 
bromide at 80 V for 2 h using 1x tris-acetate-ethylene diaminetetraacetic acid (TAE) 
37 
 
buffer. The images of the gel were taken with Bio-Rad ChemiDoc XRS+ imaging 
system (CA, USA). 
 
The SEAP marker gene coding minicircles with CMV promoter (CMV-SEAP) or 
human elongation factor-1 alpha promoter (EF1a-SEAP) were produced in 
engineered E. coli bacterial strain using MC-Easy™ System kit (MC-Easy minicircle 
DNA production kit: [MN920A-1], pMC.BESPX-MCS1 empty vector [MN100A-1], 
pMC.EF1-MCS-SV40polyA [MN502A-1], System Biosciences, USA). Like 
plasmid, the minicircles were purified by column separation according to the 
manufacturer’s instructions except to the double volumes of Buffers P1‒P3 were 
used (QIAfilter Plasmid Mega Kit, #12281, Qiagen, USA). The purity of minicircles 
was enhanced by DNA precipitation like earlier described. The minicircles were 
stored in TE-buffer (10 mM Tris, 1 mM EDTA, pH 7,4) at the concentration of ~1 
µg/µl at +4 ⁰C. The minicircles were identified by digestion and electrophoresis. 
 
10.3 PEI/DNA polyplexes 
 
PEI/DNA complexes with different nitrogen/phosphorus (n/p) ratios were prepared 
(Subrizi et al. 2009). N/p ratios were calculated in moles supposing that 325 g/mol 
corresponds one repeating unit of DNA containing one negative charge of phosphate 
and 43,1 g/mol corresponds one repeating unit of PEI having one positive charge of 
nitrogen. The total positive charges of the carrier were divided by the negative 
charges of DNA and several n/p ratios were formed (+1/2, +1, +2, +4, +6, +8, +10 
and +16). PEI/DNA complexes were produced by making PEI and DNA dilutions 
and adding the equal volume of PEI dilution to DNA dilution, both diluted in 10 mM 
Mes-Hepes buffered saline (50 mM Mes, 50 mM Hepes and 75 mM NaCl in H2O).  
When PEI solution at n/p ratio +16 was concerned, 2,1 µg corresponding 49,28 nmol  
of diluted PEI was mixed with 1 µg corresponding 3,08 nmol of diluted DNA.  The 
solution was mixed twice with a pipette and vortexed for 2 s. The complexes were 
incubated at room temperature for 2 hours. 
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10.4 DOTAP/DOPE liposomes and DOTAP/DOPE/PS/DNA lipoplexes 
 
A lipid film hydration method was used to form DOTAP/DOPE (1:1 mol/mol) 
liposomes (Mannermaa et al. 2005). The production of 0,5 ml of lipid stock solution 
was started by mixing the volumes corresponding 1,6 mmol of DOTAP and 
1,6 mmol of DOPE together. After mixing, the chloroform was dried under the 
nitrogen and the formed lipid films were further dried overnight in the vacuum 
desiccator. 0,5 ml of sterile mqH2O was added on the lipid film to form 3,2 mM 
stock solution of the lipids and the flask was spun for 30 min at 30 ⁰C in a rotavapor 
to hydrate the lipid film. The lipids were incubated at room temperature for 2 hours 
after which they were extruded through 0,1 µm membrane 21 times with Mini-
Extruder (Avanti Polar Lipids, AL, USA). The liposomes were stored at ~ +4 ⁰C for 
a week. 
 
When DOTAP/DOPE/PS/DNA lipoplexes were formed, the equal volumes of DNA 
and protamine sulfate (PS) dilutions in Mes-Hepes buffer were mixed at the ratio 
0,47 (w/w). The PS/DNA mixture was incubated for 10 min and the equal volume of 
DOTAP/DOPE liposomes diluted in sterile H2O was added to form lipoplexes at 
several n/p ratios (+4,45, +6, +8). N/p ratios were calculated in moles supposing that 
325 g/mol corresponds one repeating unit of DNA containing one negative charge of 
phosphate, PS has 21 positive charges per mole and DOTAP/DOPE stock solution 
has one positive charge per 3,2 mmol. The formed lipoplex solution was incubated 
for 2 hours. 
 
10.5 Micelle formation and PDMAEMA-based polyplexes 
 
A water addition method was used to produce copolymer micelles (Alhoranta et al. 
2011). PBuA-PDMAEMA or PS-PDMAEMA copolymers were dissolved in N-N-
dimethylformamide (DMF, ≥99,8%, #319937, Sigma) in the concentration of 
5 mg/ml and they were stirred at the room temperature overnight. mqH2O was added 
drop wise during 1 hour to form 2 mg/ml solution. The polymer solutions were 
loaded into the dialysis cells with 12000–14000 Daltons membrane (Medicell 
International Ltd, London, United Kingdom) and they were dialyzed against 2 liters 
of mqH2O to remove DMF changing dialysis H2O twice a day for two days. On the 
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third dialysis day, the dialysis buffer was changed to 0,05 M saline to form isotonic 
micelle solution. The saline buffer was changed twice a day until the micelles were 
recovered at the end of the fourth dialysis day. The ready micelles were stored at +4 
⁰C for 1 month. 
 
Copolymer/DNA complexes with varying n/p ratios (mol/mol) were formed in 
Mes-Hepes buffer. The equal volume of copolymer dilution was added to DNA 
dilution mixing with a pipette, after which the complexes were incubated for 2 hours. 
It is supposed that 314 g/mol corresponds one repeating unit of cationic PDMAEMA 
and has one positive charge of nitrogen and 325 g/mol corresponds one repeating 
unit of DNA containing one negative charge of phosphate. Because positive charges 
are located in the PDMAEMA part of copolymer, the proportion of PDMAEMA in a 
copolymer needs to be taken into account when calculating the charges of 
polyplexes. The proportion of PDMAEMA can be calculated using the molecular 
weights of blocks in the certain copolymer. For example, concerning linear 
PDMAEMA-PBuA-PDMAEMA copolymer the portion of PDMAEMA is obtained 
by the following calculation:  ଶ∗ெௐ(௉஽ெ஺ாெ஺)
ଶ∗ெௐ(௉஽ெ஺ாெ஺)ାெௐ(௉஻௨஺) . 
  
10.6 Lipid coated DNA complexes 
 
DOPE/CHEMS (3:2 mol/mol), diolein/CHEMS (3:2 mol/mol) and DPPE/CHEMS 
(3:2 mol/mol) coated complexes were prepared according to Lehtinen et al. (2008). 
PEI/DNA complexes were produced mixing equal volumes of diluted PEI and DNA 
solutions in 10 mM HEPES (pH 7,4) together. N/p ratios +2, +4, +6 and +8 were 
used with the DNA concentration of ~48 µg/µl. The lipid shields were formed by a 
detergent removal method. The total lipid content was adjusted to 1,3 μmol (half 
lipid), 2,6 μmol (full lipid) or 5,2 µmol (twice lipid) per a tube. Desired volumes of 
lipid solutions were measured to a glass tube and chloroform/methanol was dried 
under the nitrogen and in a vacuum desiccator overnight. 
 
The lipid film was dissolved with 5 % octylglucoside (OG) solution in H2O (m/v) by 
vortexing. The volumes corresponding 8 µg, 10 µg and 11,5 µg of OG were added 
on half, full and twice lipid, respectively. The mixture was warmed to 60 °C in the 
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water bath if the lipid film did not dissolve at room temperature. The volumes of 17,5 
μl, 22 μl and 25,5 μl of 100 mM Hepes pH 7,4 was added to half, full and twice lipid, 
respectively. 10 mM Hepes, pH 7,4 was added to have a volume of 500 μl of each 
lipid. The equal volume of PEI/DNA complexes were added drop wise into the lipid 
solution stirring with a magnetic stirrer at 250 rpm. After that the solution was 
diluted with 1000 μl of 10 mM Hepes drop by drop. The solution was loaded into 
dialysis cassettes (Slide-A-Lyzer Dialysis Cassette 10000 MWCO, #66380, Thermo 
Scientific, MA, USA) and dialyzed stirring at 250 rpm against 2 liters of 10 mM 
Hepes at +4 °C overnight changing the dialysis buffer after 1, 3 and 6 hours. The 
ready lipid coated DNA complexes (LCDCs) were recovered on the next day. 
 
10.7 Size measurement and zeta potential 
 
The size and zetapotential of the complexes was measured by dynamic light 
scattering. The complexes were produced like earlier described. For zeta potential 
measurement, the complexes were formed in 10 mM Hepes because of the suitable 
conductivity of the buffer for the measurement. Zetasizer APS (Malvern Instruments, 
United Kingdom) was used to study particle size and Zetasizer Nano (Malvern 
Instruments, United Kingdom) zetapotential. The setup and analysis were carried out 
by Malverns Zetasizer Software V.7.02. 
 
10.8 Gel retardation assay 
 
The complex formation efficiency of nanoparticles was studied by electrophoresis on 
agarose gel. 200‒600 ng of DNA was used per well depending on the well size of the 
comb. In order to evaluate the stability of complexes, three times excess in moles of 
negatively charged dextran sulfate (DS) was added to the complex dilution and the 
mixtures were incubated for 1 h before electrophoresis. For non-treated samples the 
same volume of Mes-Hepes or 10 mM Hepes buffer was added. Electrophoresis was 
conducted in 1 % (w/v) agarose gel with 0,15 µg/µl ethidium bromide (EtBr) at 80 V 
for  40–120 min using TAE buffer. The images of the gel were taken with Bio-Rad 
ChemiDoc XRS+ imaging system (CA, USA). 
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10.9 DNA relaxation assay 
 
The condensation efficiency and stability of complexes were determined by DNA 
relaxation assay. The complexes were produced like described earlier. 150 µl of the 
complex solution corresponding 1 µg of DNA or 1 µg of free DNA as a control was 
used per well in triplicates in a black 96-well plate. 50 µl of EtBr dilution (10 µg/µl) 
was added per well. The fluorescence was measured at the excitation wavelength of 
518 nm and the emission wavelength of 605 nm with Varioskan™ Flash Multimode 
Reader 4.00.53 (Thermo Scientific, MA, USA), after which three times excess 
(mol/mol) of dextran sulfate (50 µl) was added. The fluorescence was measured 
immediately, after 20 min, 60 min and 24 h. After the last measurement, 50 μl of 
non-ionic surfactant Triton X-100 (#807423, MP Biomedicals LLC) 10 % in H2O 
was added to wells containing LCDCs to disintegrate the complexes and the 
fluorescence was measured immediately, after 20 min, 60 min and 24 h. The 
fluorescence of the samples was divided by the fluorescence of free DNA to get 
relative fluorescence values. 
 
10.10  Cell cultures 
 
ARPE-19 cells were cultured in DMEM/F12 (#31330, Gibco) supplemented with 
10 % (v/v) of fetal bovine serum (FBS), 1 % (v/v) of 100x GlutaMAX supplement 
(#35050-038, Gibco) and 1 % (v/v) Pen-Strep. The cell culture was grown at 37 ⁰C 
in 7 % CO2 atmosphere. The cells were subcultured once a week. For transfection, 
20 000 cells were seeded per well on a 96-well plate (Nunc™ MicroWell™ Plates 
with Nunclon™ Delta Surface, #163320, Nunc). The passage number 29 was used in 
transfections. 
 
Human embryonic stem cell-derived retinal pigment epithelial cells were received 
from Heli Skottman, Ophthalmology group, Institute of Biomedical Technology, the 
University of Tampere. The cells were cultured in KnockOut DMEM (#10829-018, 
Gibco) supplemented with 15 % of KnockOut Serum Replacement (#10828-028, 
Gibco), 1% of 100x GlutaMAX supplement (#35050-038, Gibco), 1% of 100x 
NEAA (#BE13-114E, Biowhittaker), 0,2 % of 50 mM 2-Mercaptoethanol (#31350-
010, Gibco) and 50 U/ml of Pen-Strep (#17-602E, Biowhittaker) on 24-well or 
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48-well plate. The medium was changed three times a week. The cells were 
incubated at 37 ⁰C in 5% CO2 atmosphere (HERAcell 150 CO2 incubator, Thermo 
Electron Corporation, Vaasa, Finland). For transfection, 200 000 cells were seeded to 
a well on 48-well plate using the cell passages 46 and 47 (Corning® CellBIND® cell 
culture multiwell plate, #3338, Sigma-Aldrich). 
 
Human embryonic primary retinal pigment epithelial cells (HRPEpI, 6540) were 
obtained from ScienCell. The flasks were coated with poly-L-lysine (#0403, SciCell) 
0,2 or 2 µg/cm2 a day before the cell seeding. The cells were cultured in Epithelial 
Cell Medium with 2 % of FBS (#0010, SciCell), 1 % of epithelial cell growth 
supplement (#4152, SciCell) and 1 % of penicillin/streptomycin solution (#0503, 
SciCell). For transfection, 50 000 cells were seeded per well on poly-L-lysine coated 
(2 µg/cm2) 48-well plates (Corning® CellBIND® cell culture multiwell plate, #3338, 
Sigma-Aldrich). 
 
Human endothelial hybrid cell line (EaHy 926) was cultured in DMEM (#41966-
029, Gibco) supplemented with FBS (#10270, Gibco), 1% of 100x GlutaMAX 
supplement (#35050-038, Gibco) and 1 % of Pen-Strep (#17-602E, Biowhittaker). 
200 µl of 50x HAT supplement (#21060-017, Gibco) was added to 10 ml of medium 
just before medium change. The cells were subcultured twice a week. For 
transfection, 20 000 cells were seeded per well on a 48-well plate (Nunclon Surface 
48-well plate, #150687, Nunc). The cell passages 19 and 27 were used for 
transfections. 
 
10.11  Transfections 
 
hESC-RPE, primary RPE and EaHy cells were seeded on 48-well plates and 
ARPE-19 cells on 96-well plates a day before transfection. Transfection was 
conducted according to the protocol optimized by Subrizi et al. (2009). The 
complexes were prepared and incubated for two hours, after which they were added 
on the cell cultures. For ARPE-19 cells 0,6 µg of DNA and to hESC-RPE, HRPEpi 
and EaHy cells 0,8 µg of DNA was used per well. The cells were incubated with 
complexes in serum-free medium for 2 h at 37 ⁰C. After that the cells were washed 
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with D-PBS and 150 µl (ARPE-19), 200 µl (hESC-RPE) or 250 µl (EaHy and 
Human primary RPE cells) of full medium was added per well. 
10.12  Evaluation of the transfection efficiency 
 
The first samples for SEAP secretion analysis were collected on day 1 after the 
transfection and the sample taking was continued once a day extending the sample 
taking interval during the time. The sample taking was stopped once the SEAP 
secretion level decreased significantly or the viability of the cells lowered. The cell 
growing medium was collected at certain time points and the samples were 
centrifuged at 12 000 g for 30 s or 2750 g for 1 min to remove possible detached 
cells. The collected medium was stored at -20 ⁰C before analysis. The samples were 
analyzed with Great EscAPe™ SEAP Chemiluminescence Kit 2,0 (#631738, 
Clontech, USA) according to the manufacturer’s instructions. Briefly, 25 µl of 
removed medium was transferred to a luminescence plate and 75 µl of dilution buffer 
was added. In order to remove the impact of natural phosphatase enzymes, the 
samples were incubated at 65 ⁰C for 30 min. 100 µl of SEAP substrate was added per 
well and samples were incubated at room temperature ~30 min after which 
chemiluminescence was measured with Varioskan™ Flash Multimode Reader 
4.00.53 (Thermo Scientific, MA, USA). The standard curve of SEAP positive control 
was produced to convert relative light units to the quantity of SEAP. The standard 
curve covered the SEAP concetrations 0,00096–2 ng/μl. If the concentration of 
SEAP was not within the standard curve, the SEAP samples were diluted with the 
dilution buffer and the samples were analyzed again like described above. As a 
negative control, medium from non-transfected cells was used. The luminescence 
value from the full medium was used to evaluate the background effect.  
 
10.13  Evaluation of the cell viability 
 
The cell viability was estimated based on the microscope pictures and using 
AlamarBlue test. In AlamarBlue test fresh medium was added to the cells and 10 % 
of alamarBlue™ Dye (#DAL1100, Thermo Scientific) was added to the medium. 
The cells were incubated at 37 ⁰C for 2‒4 h and the medium was collected into a 
black 96-well plate. The fluorescence was measured at the excitation wavelength 540 
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nm and the emission wavelength 590 nm with VarioSkan. The relative fluorescence 
was calculated by dividing the obtained fluorescence values of the medium from the 
transfected cells by the fluorescence value of the medium collected from the wells of 
the cells that were not transfected. 
 
 
11 RESULTS 
 
11.1 Size and zetapotential measurements 
 
The size and zetapotential of nanoparticles complexed with plasmid (EBNA-CMV-
SEAP) or minicircle (CMV-SEAP or EF1a-SEAP) are collected in Table 1. Several 
n/p-ratios were used to form nanoparticles for the measurements. 
 
Table 1. Z-average size (±standard error of the mean, SEM), polydispersity index 
(PdI) and zetapotential (ZP) (±SEM) of carrier/DNA complexes. The Z-average size 
was measured in Mes-Hepes except to the size of LCDCs was measured in 10 mM 
Hepes. The setapotential of all the complexes was measured in 10 mM Hepes. 
Carrier/DNA complex 
Z-Average 
(nm) 
SEM 
(±nm) PdI 
n 
(size) 
ZP 
(mV) 
SEM 
(±mV) 
n 
(ZP) 
Plasmid (EBNA-CMV-SEAP)               
PEI +4 458 219 0.499 2    
PEI +6 181 17 0.318 7 40.0 0.4 2 
PEI +8 167 16 0.389 6 40.0 0.1 2 
PEI +10 162 16 0.380 2 - - - 
DOTAP/DOPE/PS +4,45 203 38 0.470 4 37.2 2.8 2 
DOTAP/DOPE/PS +6 130 0 0.095 2 - - - 
DOTAP/DOPE/PS +8 136 6 0.138 2 - - - 
PS-PDMAEMA linear +2 209 9 0.218 4 - - - 
PS-PDMAEMA linear +4 182 9 0.230 5 32.6 0.7 2 
PS-PDMAEMA linear +8 142 - 0.205 1 - - - 
PS-PDMAEMA linear +16 131 - 0.170 1 - - - 
PS-PDMAEMA star +2 427 - 0.219 1 34.1 0.4 2 
PS-PDMAEMA star +4 507 - 0.246 1 - - - 
PS-PDMAEMA star +8 493 - 0.189 1 - - - 
PS-PDMAEMA star +16 533 - 0.200 1 - - - 
PBuA-PDMAEMA linear +2 170 8 0.277 4 - - - 
PBuA-PDMAEMA linear +4 145 2 0.250 3 - - - 
PBuA-PDMAEMA linear +8 125 - 0.197 1 - - - 
PBuA-PDMAEMA linear +16 120 - 0.208 1 - - - 
PBuA-PDMAEMA star +2 214 8 0.307 4 33.6 0.2 2 
PBuA-PDMAEMA star +4 195 2 0.281 3 - - - 
PBuA-PDMAEMA star +8 177 - 0.438 1 - - - 
PBuA-PDMAEMA star +16 200 - 0.431 1 - - - 
DreamFect 199 - 0.277 1 - - - 
DOPE/CHEMS Half lipid PEI +6 213 33 0.352 3 -55.4 2.1 2 
DOPE/CHEMS Half lipid PEI +2 287 - 0.255 1 - - - 
DOPE/CHEMS Full lipid PEI +6 176 - 0.336 1 -58.6 1.6 2 
DOPE/CHEMS Full lipid PEI +4 151 - 0.353 1 - - - 
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Table 1 continues:        
DOPE/CHEMS Twice lipid PEI+8 96 3 0.420 2 -62.9 - - 
Diolein/CHEMS Half lipid PEI +6 179 25 0.295 4 -67.1 - - 
Diolein/CHEMS Half lipid PEI +8 145 - 0.227 1 - - - 
Diolein/CHEMS Full lipid PEI +6 175 10 0.289 2 -71.5 5.1 2 
Diolein/CHEMS Full lipid PEI +8 139 - 0.277 1 - - - 
DPPE/CHEMS Full lipid PEI +6 433 1 0.480 2 -56.3 - 1 
DPPE/CHEMS Twice lipid PEI +6 800 83 0.483 2 -77.0 - 1 
Minicircle CMV-SEAP               
PEI +6 272 83 0.356 2 - - - 
PEI +8 210 14 0.437 2 - - - 
PEI +10 172 - 0.315 1 - - - 
DOTAP/DOPE/PS +4.45 216 44 0.459 3 - - - 
PS-PDMAEMA linear +4 239 32 0.292 2 - - - 
PBuA-PDMAEMA linear +2 260 5 0.395 2 - - - 
PBuA-PDMAEMA star +2 238 29 0.359 2 - - - 
DreamFect 211 - 0.381 1 - - - 
Minicircle EF1a-SEAP               
PEI+6 701 521 0.574 2 - - - 
PEI+8 250 50 0.346 2 - - - 
PEI+10 192 - 0.342 1 - - - 
DOTAP/DOPE/PS +4.45 184 15 0.423 3 - - - 
PS-PDMAEMA linear +4 245 14 0.317 2 - - - 
PBuA-PDMAEMA linear +2 204 17 0.312 2 - - - 
PBuA-PDMAEMA star +2 247 15 0.347 2 - - - 
DreamFect 359 - 0.322 1 - - - 
        
11.2 Gel retardation assay 
 
The condensation efficiency of carrier/DNA complexes was studied by the 
electrophoresis on the agarose gel at several n/p ratios. The binding of free DNA to 
EtBr leads to visible bands on the gel. The complexes were also run with anionic DS 
to study the relaxation of DNA from the complexes. 
 
As shown in Figure 2, 3 and 4, on the most of the lanes no bands are seen on the gel 
and the complexes retard DNA completely when DS is not added. The exceptions are 
micelle/plasmid complexes formed from star-like PBua-PDMAEMA copolymer at 
n/p ratios +4 and +16. The bands can be observed on the gel although DS is not 
present (Figure 2, Lanes 16 and 17). Concerning LCDCs coated with 
diolein/CHEMS or DOPE/CHEMS, faint bands are present at the end of the lanes 
although DS is not added to the complexes (Figure 2, Lane 9; Figure 3 A, Lanes 3, 5 
and 6). 
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Figure 2. Agarose gel electrophoresis of carrier/DNA complexes with plasmid 
EBNA-CMV-SEAP. On the row A complexes without DS and on the row B the 
complexes with DS are presented. On the lane 2 and 19 the uncut plasmid was run 
and three bands can be observed that are supposed to be multimer, opened and 
supercoiled plasmid from above to downwards. On the lane 18, the plasmid digested 
by Xbal endonuclease is shown. 
1. and 20. Ladder 6. DOTAP/DOPE/PS +4,45 11. PS linear +16 
2. and 19. Uncut plasmid 7. DOTAP/DOPE/PS +6 12. PS star +4 
 (EBNA-CMV-SEAP) 8. DOTAP/DOPE/PS +8 13. PS star +16 
3. PEI +4 9. DOPE/CHEMS twice 14. PBuA linear +4 
4. PEI +6 lipid PEI +8 15. PBuA linear +16 
5. PEI +8 10. PS linear +4 16. PBuA star +4 
  17. PBuA star +16 
 
    
The bands are observed on the lanes when PEI/DNA polyplexes, 
DOTAP/DOPE/PS/DNA lipoplexes and copolymer/DNA complexes formed from 
star-like PS-PDMAEMA or star-like PBuA-PDMAEMA copolymers are run with 
DS (Figure 1). Concerning PS-PDMAEMA- and PBuA-PDMAEMA-based 
polyplexes formed from linear copolymers, only faint bands can be detected on the 
gel thought DS is present. However, minicircles formed more resistant complexes to 
DS when they were complexed with star-like PBuA-PDMAEMA copolymer 
compared with linear PBuA-PDMAEMA copolymer (Figure 4). No bands can be 
observed on the gel when LCDCs are run on the gel and DS is present (Figure 3). 
 
1     2    3     4   5    6    7    8    9   10  11 12  13  14  15 16  17  18  19  20 
1   2   3   4    5   6   7   8   9  10  11 12  13  14 15 16 17 B
A
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Figure 3. Electrophoresis of LCDCs on agarose gel. 
A. diolein/CHEMS coated complexes: 
1. ladder, 2. circular plasmid, 3. half lipid PEI +6, 4. half lipid PEI +8, 5. full lipid 
PEI +6, 6. full lipid PEI +8. On the first row complexes without DS and on the 
second row with DS are presented. 
B. DOPE/CHEMS coated complexes: 
7. ladder, 8. circular plasmid, 9. half lipid PEI +6, 10. full lipid PEI +6, 11. twice 
lipid PEI +8 12. half lipid PEI +6 with DS, 13. full lipid PEI +6 with DS, 14. twice 
lipid PEI +8 with DS. 
C. DPPE/CHEMS coated complexes: 
15. ladder, 16. circular plasmid, 17. full lipid PEI +6, 18. twice lipid PEI +6, 19. full 
lipid PEI +6 with DS, 20. twice lipid PEI +6 with DS. 
  
Figure 4. Electrophoresis of carrier/minicircle complexes on agarose gel. 
A. Minicircle CMV-SEAP, B. Minicircle EF1a-SEAP. 
The order of the samples: 1. ladder 2. circular minicircle, 3. PEI +8, 4. 
DOTAP/DOPE/PS +4,45, 5. PS linear +4, 6. PBuA linear +2, 7. PBuA star +2, 8. 
PEI +8 with DS, 9. DOTAP/DOPE +4,45 with DS, 10. PS linear +4 with DS, 11. 
PBuA linear +2 with DS, 12. PBuA star +2 with DS. 
 
1     2    3    4     5    6   7    8    9    10  11  12 1     2    3     4    5     6    7    8    9    10   11  12 
A. 
A B
C
1       2        3      4        5        6 
1      2       3     4       5       6 
7     8      9    10    11  12   13    14 
15      16      17     18      19      20 
A B
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11.3 DNA relaxation assay 
 
The release of DNA from the complexes was studied by DNA relaxation assay. 
PEI/DNA complexes, DOTAP/DOPE/PS/DNA lipoplexes and copolymer/DNA 
polyplexes disintegrated immediately after DS addition, which is shown in the 
increase in the relative fluorescence of the samples from 6–40 % to 60‒100 % 
(Figure 5). As shown in Figure 5, PEI/DNA polyplexes at n/p ratio +4 did not 
complex DNA unlike PEI at higher n/p ratios +6 and +8. The relative fluorescence of 
PEI/DNA complexes at n/p ratio +4 was 75 % already before DS addition. 
Copolymer/DNA polyplexes formed from star-like PBuA-PDMAEMA also 
produced only loose complexes which is shown as ~50 % starting relative 
fluorescence value. However, the deviation of relative fluorescence between the 
complexes formed from several star-like PBuA-PDMAEMA batches was high (data 
not shown). 
 
 
Figure 5. DNA relaxation assay of PEI/DNA complexes, DOTAP/DOPE/PS/DNA 
lipoplexes and PDMAEMA-based polyplexes. The fluorescence value of complexes 
was divided by the fluorescence of free DNA. The fluorescence was measured 
without DS and immediately, after 20 min, 60 min and 24 h of DS addition. 
 
LCDCs are stable against the effects of DS and relative fluorescence remains almost 
the same regardless of the addition of DS (Figure 6). However, the relative 
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fluorescence values at the first measuring point vary from 19 % to 45 % between the 
LCDCs. Non-ionic surfactant Triton X-100 was added to disintegrate the complexes 
but the detection of a fluorescence signal turned out difficult. Triton X-100 had 
influence on the background fluorescence value which disturbed the measurement 
(the data not shown). 
 
Figure 6. DNA relaxation assay of LCDCs. The fluorescence of complexes was 
divided by the fluorescence of free DNA. Fluorescence was measured without DS 
and immediately, after 20 min, 60 min and 24 h of DS addition. 
 
11.4 Transfections 
 
The transfection efficiency of carrier/DNA complexes was evaluated in ARPE-19 
cells, hESC-RPE, human embryonic primary RPE cells and EaHy cells. PEI polymer 
and commercially available DreamFect transfection agent were used as positive 
control carriers in transfections. The viability of cells was evaluated by microscope 
observing and with an AlamarBlue test after transfections. 
 
11.4.1 Cell cultures 
 
The viability of cells was observed with the microscope. The pictures of cells were 
taken before and after transfections (Figure 7). The differences in cell density can be 
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observed before the transfection to EaHy cells when passage numbers 19 and 27 are 
compared (Figure 7, Pictures D. and G.). 
 
 
 
 
 
Figure 7. The microscopic pictures (10x) of cells on 48-well plates before and after 
transfection. Pictures on day 0 have been taken just before transfection. 
 
hESC-RPE / PBuA-PDMAEMA star +2 (plasmid), seeding density 200 000 
cells/well, passage number (p.) 46: 
A. Day 0, B. Day 1 C. Day 24.  
EaHy / DOTAP/DOPE/PS (plasmid) +4,45, 20 000 cells/well, p. 19:  
D. Day 0, E. Day 1, F. Day 4 
EaHy / DOTAP/DOPE/PS (minicircle CMV-SEAP), 20 000 cells/well, p. 27:  
G. Day 1, H. Day 4, I. Day 6 
Human primary RPE cells / PBuA-PDMAEMA star +2 (plasmid), 50 000 cells/well, 
p. 1:  
J. Day 0, K. Day 1, L. Day 3 
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11.4.2 Transfection of ARPE-19 cells 
 
PEI/DNA complexes at n/p ratios +4, +6 and +8, DOTAP/DOPE/PS/DNA lipoplexes 
at n/p ratios +4,45, +6 and +8, star-like and linear PS-PDMAEMA/DNA and PBuA-
PDMAEMA/DNA polyplexes at n/p ratios from +2 to +16 were used in transfections 
to dividing ARPE-19 cells. Plasmid DNA EBNA-CMV-SEAP was used to form all 
the complexes. 
 
The SEAP secretion was the highest on day 2 or 3 after transfection depending on the 
complex (Figure 8). The cells were followed for 6 days after the transfection. The 
maximum SEAP secretion rate varied from 0–451 ng/h/ml. PBuA-PDMAEMA/DNA 
polyplexes from linear copolymer at n/p +2 were the only complexes that reached the 
transfection efficiency of PEI-complexes. The complexes that did not reach any 
transfection efficiency are not presented in Figure 8. 
 
 
Figure 8. The SEAP secretion rate on the logarithmic scale after transfection to 
ARPE-19 cells (n=1). Plasmid DNA is used in all the complexes. 
 
According to the data from the AlamarBlue test, the viability of ARPE-19 cells 
varied widely depending on the complex used (Figure 9). On the day 1 after the 
transfection, the lowest viability 7 % and 12 % was observed in the wells that were 
treated with star-like PS-PDMAEMA -based polyplexes at n/p ratio +8 and +16, 
0.1
1
10
100
1000
0 1 2 3 4 6
SE
AP
 (n
g/
h/
m
l)
Days after transfection
PEI +4 PEI +6 PEI +8
DOTAP/DOPE/PS +4,45 PS-PDMAEMA star +4 PS-PDMAEMA star +8
PS linear +2 PS-PDMAEMA linear +4 PBuA-PDMAEMA linear +2
PBuA-PDMAEMA linear +4
52 
 
respectively. PDMAEMA/DNA polyplexes at higher n/p ratios can be found to 
decrease more the viability compared with the other complexes and the viability of 
the cells transfected with PDMAEMA/DNA polyplexes did not always increase 
during the time after transfection. 
 
It can be shown the dependency on the viability between different n/p ratios in the 
cells that have been treated with star-like or linear PS-PDMAEMA -based or linear 
PBuA-PDMAEMA -based polyplexes. The viability is decreasing when the n/p ratio 
is increasing (Figure 9). The cells transfected with the other complexes do not show 
such an effect. The metabolic activity of the cells treated with PEI/DNA complexes 
decreased on day 1 after transfection (21‒71 % depending on the n/p ratio). 
However, the cells reached fast the viability over 100 %. The viability of the cells did 
not decrease under 80 % when the cells were transfected with 
DOTAP/DOPE/PS/DNA lipoplexes. 
 
 
Figure 9. The viability of ARPE-19 cells after transfection (n=1). Plasmid EBNA-
CMV-SEAP is used to form all the complexes. The metabolic activity is estimated 
with the AlamarBlue test. It is assumed that the transfection day is the day 0. 
 
11.4.3 Transfection of human embryonic primary RPE cells 
 
Two parallel transfections were conducted to human embryonic RPE primary cells. 
The transfections were done at the same time and the cells had the same passage 
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number 1. PEI/DNA complexes at n/p ratio +6 and +8, copolymer/DNA polyplexes 
formed from linear PS-PDMAEMA, linear PBuA-PDMAEMA and star-like PBuA-
PDMAEMA at n/p ratios +2 and +4 and DOTAP/DOPE/PS/DNA lipoplexes at n/p 
ratio +4,45 were formed with plasmid  (EBNA-CMV-SEAP) or minicircle (CMV-
SEAP or EF1a-SEAP) for the transfections. The data from transfections with 
carrier/plasmid complexes are shown in Figure 12 and with carrier/minicircle 
complexes in Figure 13. LCDCs, linear PS-PDMAEMA complexed with plasmid at 
n/p ratio +2, DreamFect/plasmid complexes, PEI/EF1a-SEAP minicircle polyplexes 
at n/p ratio +6 or +8 and PEI/CMV-SEAP minicircle polyplexes at n/p ratio +6 did 
not have any transfection efficiency. The cells were followed for 18 days. 
 
In human embryonic RPE primary cells, star-like PBuA-PDMAEMA carrier had the 
highest transfection efficiency and the production of SEAP reached ~35 ng/h/ml and 
~47 ng/h/ml when plasmid and CMV-SEAP minicircle were used in the complex 
with the polymer, respectively. Also the other carrier/plasmid complexes presented 
in Figure 12 reached the transfection efficiency of PEI/DNA polyplexes. Concerning 
minicircles, carrier/CMV-SEAP complexes produced higher transfection efficiency 
compared with carrier/EF1a-SEAP complexes. 
 
 
Figure 12. SEAP secretion rate (ng/h/ml ±SEM) on the logarithmic scale after 
transfection to human primary RPE cells with carrier/plasmid complexes (n=2). 
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Figure 13. SEAP secretion rate (ng/h/ml ±SEM) on the logarithmic scale after 
transfection to human primary RPE cells with carrier/minicircle complexes (n=2). 
 
The viability of primary RPE cells was followed for five days after the transfections 
using the AlamarBlue test. Generally, the metabolic activity stayed over 75 % after 
the transfection. Star-like PBuA-PDMAEMA -based complexes showed to decrease 
viability to ~60 % when used at n/p ratio +4. However, the cells recovered from the 
transfections reaching the viability over 90 % within 5 days from the transfection.  
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Figure 14. The viability of human primary RPE cells after transfection with 
carrier/plasmid complexes (±SEM). The metabolic activity is estimated with the 
AlamarBlue test. It is assumed that the transfection day is the day 0. 
 
 
Figure 15. The viability of human primary RPE cells after transfection with 
carrier/minicircle complexes (±SEM). The metabolic activity is estimated with the 
AlamarBlue test. It is assumed that the transfection day is the day 0. 
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11.4.4 Transfection of human embryonic stem cell-derived RPE cells 
 
PEI/DNA complexes, copolymer/DNA polyplexes formed from linear PS-
PDMAEMA, linear PBuA-PDMAEMA or star-like PBuA-PDMAEMA, and 
DOTAP/DOPE/PS/DNA lipoplexes were used in transfections complexed with 
plasmid DNA. The minicircles were used to form only PEI/DNA and 
DOTAP/DOPE/PS/DNA complexes. The cells were followed for 24 days after the 
first and 30 days after the second transfection (Figure 10). All the complexes turned 
out some transfection efficiency and the SEAP secretion rate of all the used 
complexes is shown in Figure 10. 
 
The maximum SEAP secretion rate was almost at the same level between most of the 
transfections (0,1–1 ng/h/ml) (Figure 10). The highest SEAP secretion rate of 
~18 ng/h/ml and the longest secretion period was reached with DOTAP/DOPE/PS 
liposomes complexed with plasmid.  The cells transfected with DOTAP/DOPE/PS 
liposomes complexed with plasmid or EFa1-SEAP minicircle reached higher SEAP 
secretion level after the transfection compared with the other complexes. The 
duration of the SEAP secretion was also longer when the cells were treated with the 
concerned lipoplexes. The marker protein secretion started to wane significantly after 
13 days after the transfections. Only a low SEAP signal from the cells treated with 
PEI/plasmid complexes at n/p ratio +6 could be detected on the day 30. 
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Figure 10. The SEAP secretion rate (ng/h/ml ±SEM) on the logarithmic scale after 
the transfection with carrier/DNA complexes to hESC-RPE cells. The results from 
two transfections are combined in the figure. 
 
The metabolic activity of hESC-RPE was assessed with the AlamarBlue test (Figure 
11). The viability of the cells did not decrease under 65 % after the transfections with 
any complexes. All the cells reached the viability of ~100 % after a few days from 
the transfection. However, copolymer/DNA complexes at high n/p ratios were not 
used for transfection of hESC-RPE and thus, the data from their impact on the cell 
viability is not available. 
 
0.0001
0.001
0.01
0.1
1
10
100
0 1 2 3 6 10 13 17 24 30
SE
AP
 n
g/
h/
m
l
Days after transfection
PEI+6 (n=2) PEI +8
PEI +10 DOTAP/DOPE/PS +4,45
PS-PDMAEMA linear +2 PS-PDMAEMA linear +4
PBuA-PDMAEMA linear +2 PBuA-PDMAEMA linear +4
PBuA-PDMAEMA star +2 PBuA-PDMAEMA star +4
PEI +10 (minicircle CMV-SEAP) PEI +10 (minicircle EF1a-SEAP)
DOTAP/DOPE/PS +4,45 (minicircle CMV-SEAP) DOTAP/DOPE/PS +4,45 (minicircle EF1a-SEAP)
58 
 
 
Figure 11. The viability of hESC-RPE after the transfections (±SEM). The metabolic 
activity is estimated with the AlamarBlue test.  It is assumed that the transfection day 
is the day 0. 
 
11.4.5 Transfection of endothelial cells 
 
Two transfections were conducted to EaHy cells. EaHy cells start to die after 
growing confluent on the wells, which leads to a limited follow-up period after a 
transfection. The viability of cells was assessed with the AlamarBlue test and with 
the microscope, and SEAP sample taking was stopped when cell density was 
decreasing after the reached confluence. After the first transfection, the cells were 
followed for seven days, while after the second transfection the cells died before they 
reached the fifth following day. The cells with passage numbers 19 and 27 were used 
for the first and the second transfection, respectively. 
 
Both plasmid (EBNA-CMV-SEAP) and minicircles (CMV-SEAP and EF1a-SEAP) 
were used in transfections. Plasmid was complexed with PEI at n/p ratios +6, +8 and 
+10, DOTAP/DOPE/PS liposomes at n/p ratio +4,45, star-like PS-PDMAEMA and 
linear and star-like PBuA-PDMAEMA copolymers at n/p ratios 2 and 4. Plasmid was 
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also condensed with DreamFect. The following LCDCs complexed with plasmid 
were formed: DOPE/CHEMS half lipid PEI +6, full lipid PEI +6 and twice lipid PEI 
+8, diolein/CHEMS half lipid PEI +6 and full lipid PEI +6, and DPPE/CHEMS half 
and full lipid PEI +6. PEI polymer at n/p ratio +8 and DOTAP/DOPE/PS/DNA 
liposomes at n/p ratio +4,45 were used to complex both the minicircles.  
 
When the SEAP secretion reached its maximum value after the transfections, it 
stayed almost at the same level until the cells started to die (Figure 16). Transfection 
with carrier/minicircle complexes reached higher SEAP secretion level than 
complexes formed with plasmid. The transfection was repeated with complexes 
which turned out to have transfection efficiency in the first transfection. The 
complexes formed from linear PS-PDMAEMA at n/p ratio +2, star-like and linear 
PBuA-PDMAEMA at n/p ratio +4 and full and twice lipid LCDCs did not reach any 
transfection efficiency except for DPPE/CHEMS full lipid complexes. In Figure 16 
is presented the SEAP secretion rate after the transfections with the complexes that 
were used in the first or the first and the second transfections. As against, into Figure 
17 is collected the SEAP secretion data from the cells treated with the complexes that 
were used only in the second transfection. 
 
 
Figure 16. SEAP secretion (±SEM) on the logarithmic scale after the transfection to 
EaHy cells (Day 1–4: n=1 or 2, day 6–7 n=1). Both the plasmid and the minicircles 
(mc) were used in transfections. The data from the cells transfected with linear PS-
PDMAEMA -based complexes is not shown on day 3 because of a mistake in sample 
taking. 
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Figure 17. SEAP secretion after transfection with plasmid or minicircle to EaHy 
cells. CMV-SEAP or EF1a-SEAP minicircles (mc) were used to form complexes 
except to DPPE/CHEMS coated PEI/DNA complexes were formed with EBNA-
CMV-SEAP plasmid. 
 
The AlamarBlue test showed that the metabolic activity of EaHy cells after the first 
transfection decreased under the relative fluorescence value 50 % when the cells 
were transfected with many of the complexes (Figure 18). Generally, lipid-based 
complexes had higher viability compared with many polymer-based complexes. The 
cells recovered during the follow-up period except for the cells that were treated with 
star-like PBuA-PDMAEMA -based polyplexes at n/p +4 (Figure 18). After the 
second transfection, the cells reached the confluence earlier and the viability 
decreased earlier (Figure 19). Additionally, according to the microscope pictures the 
cell density was higher after the second transfection compared with the first one 
(Figure 7). The results from the AlamarBlue test after the first and second 
transfection are not combined because high differences in viability between the 
transfections were obtained. 
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Figure 18. The viability of EaHy cells after the first transfection (p.19). The 
metabolic activity is estimated with the AlamarBlue test. It is assumed that the 
transfection day is the day 0. 
 
 
Figure 19. Viability of EaHy cells after the second transfection (p. 27). The 
metabolic activity is estimated with the AlamarBlue test. It is assumed that the 
transfection day is the day 0. 
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12 DISCUSSION 
 
The eye is an optimal target for gene therapy because it is a well-defined, small 
organ and thus, with low drug doses is possible to obtain a therapeutic effect. 
Additionally, the eye is an immune-privileged site which means that the likelihood of 
immune responses provoked by gene delivery agents is decreased (Strauss 2005). In 
successful transfection, the carrier/DNA complexes need to fulfill the following 
requirements: 1) The complexes need to be stable enough; 2) The nanoparticles need 
to be taken up into the cells; 3) The carrier must protect DNA from the degradation. 
The balance between the complex sufficient stability and the minimal toxicity needs 
to be found to have efficient transfection. In vivo circumstances set more challenge 
compared with in vitro models because the complexes need to achieve the target 
tissue. In the case of AMD, the complexes are supposed to be administered 
intravitreally which means that they need to diffuse through the vitreous to reach the 
posterior eye. 
 
12.1 Complex characterization 
 
The carrier/DNA complexes are assumed to have interactions with the components 
of an anionic cell membrane like glycosaminoglycans (GAGs), which has impact on 
the cellular entry and stability of carrier/DNA-complexes (Ruponen et al. 2001). 
With a gel retardation assay and DNA relaxation assay, it can be studied how anionic 
components have impact on the complex stability. Anionic DS is assumed to mimic 
the influence of GAGs on the complexes and to have interactions with positively 
charged nanoparticles releasing DNA from the complexes. Size and zetapotential 
measurements give additional information on the complex formation and 
reproducibility of the process. The particle size has also been observed to have 
impact on the cell uptake mechanism and the transfection efficiency and thus, it is 
important to control it (Rejman et al. 2004; Masotti et al. 2009). 
 
12.1.1 PEI/DNA polyplexes 
 
In this study, PEI/DNA complexes condensed DNA efficiently when the n/p ratio 
was over +6 and DS broke the interactions between PEI and DNA efficiently 
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(Figure 2). The size of PEI/plasmid complexes at n/p ratio 6–10 was 161–180 nm 
and slightly bigger complexes were obtained when PEI was complexed with 
minicircles (Table 1). PEI complexes at n/p ratio +4 protected plasmid DNA in gel 
retardation assay but not in the DNA relaxation assay. In the DNA relaxation assay, 
complexes did not form, which can be seen in the high relative fluorescence value 
already before DS addition. According to the size measurement, the size of PEI +4 
nanoparticles varied significantly between measurements and thus, the production of 
PEI/DNA complexes at n/p ratio +4 was not reproducible (Table 1). Due to the high 
deviation in the size of PEI/DNA complexes at n/p ratio +4, they were not selected 
for transfections to hESC-RPE, EaHy and human primary RPE cells. 
Controversially, in the other studies PEI has been shown to retard DNA, when the 
n/p ratio is higher than 1,5–2 (Honoré et al. 2005, Bertschinger et al. 2006). 
However, the calculation of n/p ratios might vary between studies and therefore the 
comparison of n/p ratios is difficult. 
 
12.1.2 DOTAP/DOPE/PS/DNA lipoplexes 
 
In the studies of Mannermaa et al. (2005), DOTAP/DOPE/PS/DNA lipoplexes were 
used at n/p ratio +4,45 in transfections to ARPE-19 cells. In addition to the n/p ratio 
+4,45, DOTAP/DOPE/PS/DNA lipoplexes with the higher n/p ratios were formed 
and characterized in this experimental work. However, in the gel retardation assay 
any difference between n/p ratios +4,45, +6 and +8 could not be detected (Figure 2). 
DS liberated DNA easily from the liposomes at any n/p ratio. The size of more 
positively charged DOTAP/DOPE/PS/DNA lipoplexes was ~70 nm smaller (130–
136 nm) compared with the liposomes at n/p ratio +4,45 (203 nm) and the effect of 
higher n/p ratio and thus, the smaller size of nanoparticles was studied in the 
transfection to ARPE-19 cells. 
 
12.1.3 PDMAEMA-based polyplexes 
 
According to the gel retardation assay and the DNA relaxation assay, PBuA-
PDMAEMA and PS-PDMAEMA micelles formed complexes with both plasmid and 
minicircle DNA (Figures 2, 3, 4, 5 and 6). Alhoranta et al. (2011) have earlier 
produced and studied the same copolymers, and they observed that both star-like and 
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linear PBuA-PDMAEMA and PS-PDMAEMA copolymers condense DNA in the gel 
retardation assay when the n/p ratio is 2 or higher. That is in the line with the results 
obtained with linear PBuA-PDMAEMA and PS-PDMAEMA -based polyplexes in 
this study. 
 
Star-like PBuA-PDMAEMA micelles did not condense plasmid DNA efficiently and 
complexes were loose, which can be seen as bands on the agarose gel after the 
electrophoresis although DS is not present (Figure 2). The batch of star-like PBuA-
PDMAEMA micelles might have impact on the condensation efficiency in this 
study: In the gel retardation assay of PBua-PDMAEMA/minicircle complexes, star-
like PBuA-PDMAEMA compolymers condensed minicircles efficiently when a 
different micelle batch was used (Figure 4). 
 
Linear PS-PDMAEMA and PBua-PDMAEMA copolymers protected plasmid DNA 
more strongly than star-like copolymers and DNA was released only partly from 
linear PDMAEMA-based complexes after the DS addition in electrophoresis 
(Figure 2). The same effect was observed in the studies of Alhoranta et al. (2011). 
The authors concluded that linear copolymers condense DNA more efficiently than 
star-like copolymers. Additionally, they observed the size of nanoparticles formed 
from linear copolymers was smaller in comparison with micelles produced from star-
like copolymers. Also in this study, the Z-average size of linear copolymer/DNA 
polyplexes was smaller (120–245 nm) than star-like copolymer/DNA complexes 
(177–533 nm) except for the micelles formed with CMV-SEAP minicircle. Star-like 
and linear micelles complexed with CMV-SEAP minicircles had almost the same 
sizes (238–260 nm). The bigger size of polyplexes formed from star-like 
PDMAEMA-copolymers might result from the different geometry of polymers since 
star-like copolymers have six arms. 
 
12.1.4 Lipid coated DNA complexes 
 
Anionic LCDCs did not disintegrate after DS addition in the gel retardation assay 
and the DNA relaxation assay. As observed earlier, DOPE/CHEMS and 
diolein/CHEMS coated complexes protect DNA against DS but non-ionic surfactant 
Triton X-100 can liberate DNA from the complexes (Subrizi 2004; Lehtinen et al. 
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2008). The LCDCs are supposed not to disintegrate easily because a negatively 
charged lipid coat protects a positively charged PEI/DNA core (Lehtinen et al. 2008). 
However, with diolein/CHEMS and DOPE/CHEMS coated complexes faint bands 
can be seen at the end of the lanes as low as <0,5 kilobases in this study. The 
explanation for the presence of the bands is not known. Possibly, LCDCs released 
some DNA after the electrophoresis run. 
 
The size of LCDCs was not as large as expected for the results of the size 
measurement of PEI/DNA polyplexes. Lehtinen et al. (2008) have observed that the 
size of polyplexes increased tens of nanometers after coating with DOPE/CHEMS 
lipid shield. In this study, the Z-average size of DOPE/CHEMS full lipid PEI +6 
complexes was smaller than the Z-average size of PEI/DNA complexes at the n/p 
ratio +6 without coating (Table 1). The high polydispersity index of the Z-average 
value concerning LCDCs might explain this phenomenon. When there is a wide 
spectrum of particle size in the sample, Z-average value might not be an informative 
parameter to evaluate the particle size. The size of DPPE/CHEMS coated complexes 
was the highest varying between 430–800 nm. 
 
12.2 Transfection efficiency of complexes 
 
The secretion of marker protein, SEAP, was followed after transfections to RPE and 
endothelial cells to evaluate the efficiency of transfections. If the studied 
carrier/DNA complexes show sufficient potential to further studies, the marker gene 
can be replaced with a gene that expresses a therapeutic protein. For example, 
ranibizumab is an anti-angiogenic monoclonal VEGF-antibody that inhibits VEGF-A 
and it is used for the treatment of exudative AMD (Solomon et al. 2014). Thus, the 
gene that produces ranibizumab is a possible transgene for the gene delivery in 
exudative AMD. Ranibizumab has been observed to neutralize secreted VEGF at the 
minimum concentration of 60 ng/ml in vitro and this level gives some insight into a 
desirable level of a marker protein secretion to make the carrier/DNA complex 
potential for clinical applications (Klettner and Roider 2008). In this study 
encouraging results were received with many complexes after transfections 
concerning the possibility to further studies. 
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12.2.1 DOTAP/DOPE/PS/DNA lipoplexes 
 
DOTAP/DOPE/PS lipoplexes reached or exceeded the transfection efficiency of the 
positive control in hESC-RPE, EaHy and human primary RPE cells and they showed 
low toxicicity in this study. Earlier DOTAP/DOPE/PS/DNA lipoplexes have been 
investigated in transfection studies in Chinese hamster ovary (CHO) cells and ARPE-
19 cells also with encouraging results (Sorgi et al. 1997; Mannermaa et al. 2005). 
Condensing DNA with PS has been shown to increase the transfection efficiency of 
DOTAP/DOPE liposomes 12–222-fold compared DOTAP/DOPE liposomes alone in 
CHO cells (Sorgi et al. 1997). The condensation of DNA with PS has also shown to 
decrease cytotoxicity. The reason for that is supposed to lie in lower cationic lipid 
concentration when cationic PS neutralizes negatively charged DNA. Transfections 
with DOTAP/DOPE/PS/DNA lipoplexes to RPE cells was investigated by 
Mannermaa et al. (2005) and the secretion of SEAP in filter-cultured, differentated 
ARPE-19 cells was measured. According to the results, DOTAP/DOPE/PS/DNA 
lipoplexes (+4,45) had significant transfection efficiency compared with PEI/DNA 
complexes and the secretion of SEAP lasted almost two months. 
 
In ARPE-19 cells, transfection with DOTAP/DOPE/PS/DNA lipoplexes was not 
successful but the SEAP secretion stayed at a low level in this study (Figure 8). 
Several n/p ratios of lipoplexes were examined in transfections to ARPE-19 cells but 
higher n/p ratios with smaller size did not transfect the cells. However, this was 
expected because the larger lipoplexes have been observed to have better transfection 
efficiency compared with the smaller ones (Masotti et al. 2009). The reason for the 
failed transfection with lipoplexes to ARPE-19 cells might lie in different 
transfection circumstances compared with the study of Mannermaa et al. (2005). 
Dividing ARPE-19 cells were used in this study as opposite to the study of 
Mannermaa et al. (2005) that was conducted with non-dividing, differentiated cells. 
Also the possibility of imperfect liposome formation before the transfection to 
ARPE-19 cells may be considered. 
 
Despite unexpected results in ARPE-19 cells, in hESC-RPE, EaHy and human 
primary RPE cells were more successful. In EaHy cells 
DOTAP/DOPE/PS/minicircle lipoplexes had almost ten times higher transfection 
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efficiency (~115 ng/h/ml) on days 1–3 after transfection compared with 
DOTAP/DOPE/PS/plasmid lipoplexes (Figure 16). Contrary, in hESC-RPE and 
human primary RPE cells the liposomes complexed with plasmid had higher 
transfection efficiency (18 ng/h/ml and 12 ng/h/ml, respectively) and the secretion of 
a marker protein lasted longer compared with the transfection with 
DOTAP/DOPE/PS/minicircle lipoplexes (Figures 12, 13 and 16). 
 
The marker protein secretion lasted about 20 days from the transfection day in hESC-
RPE but the secretion of the marker protein stayed as low as under 20 ng/ml/h and 
even EF1a promoter could not prevent the silencing of the transgene expression. 
EF1a is a strong promoter of human origin and it is widely present in many human 
tissues, while CMV has virus origin (Uetsuki et al. 1989, Boshart et al. 1985). Based 
on their  different backgrounds, EF1a is supposed to have longer transfection 
efficiency compared with CMV promoter in transfections to stem cells resulting from 
the silencing phenomenon of the transgene when a CMV promoter is used (Liu et al. 
2009). However, the superiority of EF1a promoter over CMV promoter was not 
illustrated in this study. 
 
12.2.2 PDMAEMA-based polyplexes 
 
The transfection efficiency of PDMAEMA-based block copolymers was earlier 
evaluated in ARPE-19 and CV1-P cells (Alhoranta et al. 2011). When the 
transfection efficiency was studied with β-galactosidase gene, PBuA-PDMAEMA 
copolymers at n/p ratios +2 and +4 showed the highest expression level of the marker 
protein. In this study, PBuA-PDMAEMA-based polyplexes were also efficient in the 
transfections and thus, the results obtained in this study support the earlier 
observations but some differences are still found. 
 
In ARPE-19 cells linear PBuA-PDMAEMA -based polyplexes at n/p ratio +2 
reached the SEAP secretion level of ~450 ng/h/ml while star-like PBuA-PDMAEMA 
-based complexes showed to have only low ability to transfect ARPE-19 cells in this 
study. In the study of Alhoranta et al. (2011) controversially results were obtained 
concerning the architecture of the polymers: Star-like PBuA-PDMAEMA -based 
polyplexes did not show any transfection efficiency and successful results were 
68 
 
obtained with linear PBuA-PDMAEMA -based complexes in ARPE-19 cells. The 
reason for the low transfection efficiency of star-like PBuA-PDMAEMA -based 
complexes in ARPE-19 cells in this study might lie in the problems in micelle 
formation. If the micelles were not formed properly, the transfection efficiency 
remained low. New micelle solutions were made for the other transfections and 
higher transfection efficiency was observed with the other cell types. 
 
The transfection to hESC-RPE and human primary RPE was successful with 
PDMAEMA-based polyplexes: both star-like and linear PBua-PDMAEMA -based 
and linear PS-PDMAEMA -based polyplexes at n/p ratio 2 and 4 reached the 
transfection efficiency of PEI/DNA polyplexes. Significant differences in the 
transfection efficiency or the duration of SEAP secretion between different 
polyplexes or n/p ratios were not observed in hESC-RPE. In human primary RPE 
cells, star-like PBuA-PDMAEMA -based complexes at n/p ratio +2 showed to have 
high transfection efficiency compared with the other complexes reaching the 
maximal transgene secretion rate of 50 ng/ml/h. The SEAP was also secreted longer 
when human primary RPE cells were transfected with PDMAEMA-based polyplexes 
compared with PEI/DNA complexes. The cells were followed only for 18 days and 
the secretion of SEAP was still detectable when the sample taking was stopped. 
Thus, it was not got an answer to the question how long the cells could have secreted 
SEAP after the transfection with PDMAEMA-based carriers in human primary RPE 
cells in this study. 
 
CMV-SEAP minicircle showed better transfection efficiency in human primary RPE 
and EaHy cells compared with polyplexes with plasmid. The transfection efficiency 
of PBuA-PDMAEMA-based polyplexes at n/p ratio +2 with CMV-SEAP minicircle 
was on days 1–3 from the transfection about two times higher than the transfection 
efficiency of corresponding complexes with plasmid in human primary RPE cells. In 
EaHy cells, linear and star-like PBuA-PDMAEMA -based polyplexes at n/p ratio +2 
and linear PS-PDMAEMA -based polyplexes at n/p ratio +4 with CMV-SEAP 
minicircle showed ~3,5–10 times higher transfection efficiency compared with 
corresponding plasmid complexes depending on the carrier. 
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Cytotoxicity has been observed as a problem with the PDMAEMA-based carriers at 
least at higher n/p ratios and it has led to the modifications of PDMAEMA polymers 
(van de Wetering et al. 1998, Alhoranta et al. 2011). The n/p ratio needs to be high 
enough for proper complex formation but not rise too high because of high 
cytotoxicity (van de Wetering et al. 1998). In EaHy cells, micelles reached only low 
transfection efficiency and the reason why PDMAEMA-based complexes did not 
achieve better results might lie in high cytotoxicity. The viability of EaHy cells 
decreased strongly after transfection with PDMAEMA-based complexes. 
Additionally, the viability of ARPE-19 cells was studied when the cells were 
transfected with PDMAEMA-based polyplexes at the wide range of n/p ratios from 
+2 to +16. It was shown that high n/p ratios +8 and +16 had harmful effects on the 
metabolic activity of the cells. When n/p ratio +16 was used, not any transfection 
efficiency was observed in ARPE-19 cells and the reason for that is probably the 
high cytotoxicity. 
 
12.2.3 Lipid coated DNA complexes 
 
The transfection efficiency of LCDCs was evaluated in EaHy and human primary 
RPE cells in this study. In EaHy cells, DOPE/CHEMS, diolein/CHEMS and 
DPPE/CHEMS coated complexes did not reach the transfection efficiency of 
uncoated PEI and even ~10–30 times lower transfection efficiency was observed in 
comparison with uncoated PEI +6 complexes. In human primary RPE cells LCDCs 
did not reach any detectable transfection efficiency. 
 
Subrizi (2004) has studied the transfection efficiency of diolein-CHEMS coated 
LCDCs in ARPE-19 cells and LCDCs did not show any transfection efficiency in 
that study. However, the transfection with diolein/CHEMS full lipid PEI/DNA +8 
was successful to monkey kidney fibroblast (CV1-P) cells and 2,5 times higher 
transfection efficiency compared with uncoated PEI/DNA +8 complexes was 
detected. DOPE/CHEMS coated complexes was also studied in CV1-P cells but 
efficient transfection was not observed (Lehtinen et al. 2008). Lehtinen et al. (2008) 
also showed that PEGylation of LCDCs increased the cell uptake, but transfection 
efficiency was lower with PEGylated complexes compared with LCDCs without 
coating. However, studies in KB cell line, which is a subline of the ubiquitous 
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keratin-forming tumor cell line HeLa, showed that DOPE/CHEMS and 
DOTAP/CHEMS coated PEI/DNA complexes at n/p ratio 4 have higher transfection 
efficiency compared with uncoated polyplexes (Guo et al. 2002). The reason for the 
controversial results might lie in the differences in the cell uptake of LCDCs between 
the cell lines. If LCDCs can not enter the RPE cells, it can probably explain why 
LCDC are not efficient gene delivery vehicles in RPE cells. 
 
In this study, LCDCs with a new lipid composition of LCDC was also examined 
when DPPE lipid was mixed with CHEMS to form the lipid shield to PEI/DNA 
complexes. It was earlier shown that DPPE might reach a hexagonal state which is a 
desired property concerning endosomal escape of the complexes in the cell 
(Ramezani et al. 2009). However, the transfection efficiency of the complexes with 
DPPE/CHEMS lipid shield stayed at low level in EaHy cells. One reason for that 
might be the large Z-average size of nanoparticles that was 433–800 nm depending 
on the complex. 
 
12.3 Future perspectives 
 
The further development of PBuA-PDMAEMA-based complexes with episomal 
plasmid or minicircle with CMV-promoter for transfections to RPE cells is justified 
according to this study because positive results were obtained compared with 
positive control and reasonable marker protein secretion levels were obtained. 
However, the possible toxicity of PDMAEMA-based polymers needs to be taken 
account. Because human primary RPE cells and ARPE-19 cells were followed only 
for 18 and 6 days, respectively, more information is needed to evaluate the duration 
of the marker protein secretion before their potential to in vivo studied can be 
confirmed. In addition, all the experiments were conducted with dividing RPE cells 
in this study. The transfection of non-dividing cells is more challenging and RPE 
cells do not divide in vivo, which leads to a need to investigate the transfection 
efficiency of carrier/DNA complexes also in non-dividing RPE cells. 
 
The attractive results were obtained when EaHy cells and hESC-RPE were 
transfected with DOTAP/DOPE/PS/DNA lipoplexes with episomal plasmid and 
minicircle with EF1a-promoter. However, in hESC-RPE transfection efficiciency 
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lasted only 20 days and the secretion of marker protein stayed at low level. 
Concerning the cell replacement therapy, the possibility to transfect hESC-RPE cells 
before their transplantation to produce therapeutic protein would not be efficient 
according to the results with the carriers studied in this experimental work. However, 
the further transfection studies to endothelial cells with DOTAP/DOPE/PS/DNA 
lipoplexes would be interesting and the transfection of endothelial cell line that could 
be followed longer time could give more information on the transgene expression 
duration. 
 
 
13 CONCLUSIONS 
 
The focus of this study was to investigate gene delivery to the diseases of the 
posterior eye. Non-viral transfection to RPE cells and endothelial cells was studied in 
vitro using several combinations of carriers and DNA forms. According to the 
results, it can be concluded that PBuA-PDMAEMA-based complexes showed to 
have high transfection efficiency in human embryonic primary RPE cells and ARPE-
19 cells, while attractive results were obtained when EaHy cells were transfected 
with DOTAP/DOPE/PS/DNA lipoplexes. In hESC-RPE, DOTAP/DOPE/PS/DNA 
complexes exceeded the transfection efficiency of the positive control but the marker 
protein secretion level remained low lasting ~20 days. Transefctions did not succeed 
with LCDCs.  In addition to episomal plasmid, minicircles showed to be interesting 
DNA forms for transfections and in hESC-RPE and EaHy cells the high transfection 
efficiency was achieved when the minicircle with EF1a promoter was used in 
transfections, while minicircle with CMV promoter showed to be more efficient in 
transfections to human primary RPE cells. However, more investigation is needed to 
obtain more information on the duration of transgene expression in RPE and 
endothelial cells and the transfection efficiency of the complexes in non-dividing 
cells. 
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